CurAegis (CRGS) 10-Q 5 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 30, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'TORVEC INC	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	45,716,298
Amendment Flag	'false	'
Entity Central Index Key	'0001063197	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$5,432,000	$1,072,000
Accounts receivable	1,000	0
Inventories, net	13,000	0
Prepaid expenses and other current assets	47,000	31,000
Total current assets	5,493,000	1,103,000
Property and Equipment:	'	'
Office equipment and software	202,000	202,000
Shop equipment	210,000	210,000
Leasehold improvements	253,000	253,000
Transportation equipment	165,000	165,000
	830,000	830,000
Less accumulated depreciation and amortization	439,000	396,000
Net property and equipment	391,000	434,000
Total Assets	5,884,000	1,537,000
Current Liabilities:	'	'
Notes payable, current portion	23,000	48,000
Accounts payable	196,000	58,000
Accrued liabilities	69,000	70,000
Deferred revenue	20,000	20,000
Total current liabilities	308,000	196,000
Notes payable, net of current portion	4,000	6,000
Total Liabilities	312,000	202,000
Commitments and other matters (Note H)	0	0
Preferred stock, value issued	'	'
Common stock, $.01 par value, 400,000,000 shares authorized; shares issued and outstanding at March 31, 2014 and December 31, 2013: 45,716,298 and 45,716,298, respectively	457,000	457,000
Additional paid-in capital	71,362,000	66,645,000
Deficit accumulated during the development stage	-66,666,000	-65,936,000
Total Stockholders' Equity	5,572,000	1,335,000
Total Liabilities and Stockholders' Equity	5,884,000	1,537,000
Preferred Class C [Member]	'	'
Current Liabilities:	'	'
Preferred stock, value issued	162,000	162,000
Preferred Class C-2 [Member]	'	'
Current Liabilities:	'	'
Preferred stock, value issued	250,000	0
Preferred Class A [Member]	'	'
Current Liabilities:	'	'
Preferred stock, value issued	6,000	6,000
Preferred Class B [Member]	'	'
Current Liabilities:	'	'
Preferred stock, value issued	$1,000	$1,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
			Preferred Class C [Member]	Preferred Class C [Member]	Preferred Class C-2 [Member]	Preferred Class C-2 [Member]	Preferred Class A [Member]	Preferred Class A [Member]	Preferred Class B [Member]	Preferred Class B [Member]
Preferred stock, par value (in Dollars per share)	$0.01	$0.01	'	'	'	'	'	'	'	'
Preferred stock, shares authorized	100,000,000	100,000,000	16,250,000	16,250,000	25,000,000	25,000,000	3,300,000	3,300,000	300,000	300,000
Preferred stock, cumulative dividend per share (in Dollars per share)	'	'	$0	$0	$0	$0	$0.40	$0.40	$0.50	$0.50
Preferred stock, shares issued	'	'	16,250,000	16,250,000	25,000,000	0	587,101	587,101	67,500	67,500
Preferred stock, shares outstanding	'	'	16,250,000	16,250,000	25,000,000	0	587,101	587,101	67,500	67,500
Common stock, par value (in Dollars per share)	$0.01	$0.01	'	'	'	'	'	'	'	'
Common stock, shares authorized	400,000,000	400,000,000	'	'	'	'	'	'	'	'
Common stock, shares issued	45,716,298	45,716,298	'	'	'	'	'	'	'	'
Common stock, shares outstanding	45,716,298	45,716,298	'	'	'	'	'	'	'	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		210 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Revenue	$1,000	$0	$513,000
Cost of Goods Sold	27,000	0	404,000
Gross Margin	-26,000	0	109,000
Research and development:	'	'	'
R&D costs, excluding stock-based compensation expense	359,000	226,000	17,926,000
Stock-based compensation expense related to options and warrants	17,000	32,000	1,905,000
Total research and development	376,000	258,000	19,831,000
General and administrative:	'	'	'
G&A costs, excluding stock-based compensation expense	332,000	311,000	30,489,000
Stock-based compensation expense related to options and warrants	-4,000	197,000	20,789,000
Total general and administrative	328,000	508,000	51,278,000
Asset impairments	0	0	1,071,000
Total costs and expenses	704,000	766,000	72,180,000
Loss from operations	-730,000	-766,000	-72,071,000
Reversal of liability on cancellation of debt	0	0	1,541,000
Gain on litigation settlement	0	0	1,900,000
Other income	0	3,000	308,000
Loss before income tax benefits	-730,000	-763,000	-68,322,000
Income tax benefits	0	0	384,000
Net Loss	-730,000	-763,000	-67,938,000
Net loss attributable to non-controlling interest in subsidiary	0	0	1,272,000
Net Loss attributable to Torvec, Inc.	-730,000	-763,000	-66,666,000
Preferred stock beneficial conversion feature	4,250,000	0	10,595,000
Issuance of warrants to preferred shareholders	0	0	812,000
Preferred stock dividends	66,000	66,000	2,544,000
Net Loss attributable to Torvec, Inc. common stockholders	($5,046,000)	($829,000)	($80,617,000)
Net Loss per common share attributable to stockholders of Torvec, Inc.:	'	'	'
Basic and Diluted (in Dollars per share)	($0.11)	($0.02)	'
Weighted average number of shares of common stock:	'	'	'
Basic and Diluted (in Shares)	45,716,000	45,716,000	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended		210 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:	'	'	'
Net loss	($730,000)	($763,000)	($67,938,000)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation and amortization	43,000	32,000	2,882,000
Gain on sale / disposition of fixed assets	0	0	-74,000
Gain on sale of Ice Engineering license	0	0	-1,900,000
Loss on impairment of license	0	0	1,071,000
Expenses financed via note with related party	0	0	27,000
Impairment of goodwill	0	0	19,000
Common stock issued for services	0	0	13,844,000
Compensatory common stock	0	0	2,463,000
Shares issued for future consulting services	0	0	103,000
Common stock issued in connection with commercializing event plan	0	0	63,000
Stock-based compensation related to stock options and warrants	13,000	229,000	22,429,000
Compensation expense attributable to common stock in subsidiary	0	0	619,000
Stockholder contribution of services	0	0	4,220,000
Contribution to capital, Ford Truck	0	0	16,000
Reversal of liability	0	0	-1,541,000
Changes in:	'	'	'
Accounts receivable	-1,000	0	-1,000
Inventories	-13,000	-15,000	-13,000
Prepaid expenses and other current assets	-16,000	-18,000	125,000
Deferred revenue / liabilities	0	0	-71,000
Accrued payroll taxes	-2,000	-51,000	-133,000
Accounts payable and other accrued expenses	139,000	-32,000	4,116,000
Net cash used in operating activities	-567,000	-618,000	-19,674,000
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	0	-11,000	-640,000
Cost of acquisition	0	0	-16,000
Proceeds from sale of license	0	0	1,900,000
Proceeds from sale of fixed assets	0	0	59,000
Net cash (used in) provided by investing activities	0	-11,000	1,303,000
Cash flows from financing activities:	'	'	'
Net proceeds from sales of common stock and upon exercise of options and warrants	0	0	9,223,000
Net proceeds from sales of preferred stock	4,954,000	0	14,885,000
Net proceeds from sale of subsidiary stock	0	0	234,000
Net proceeds from issuance of notes payable	0	0	57,000
Repayments of notes payable	-27,000	-29,000	-310,000
Proceeds from loans	0	0	335,000
Repayments of loans	0	0	-109,000
Repayment of officer & stockholder loans and advances	0	0	-147,000
Distributions	0	0	-365,000
Net cash provided by (used in) financing activities	4,927,000	-29,000	23,803,000
Net increase (decrease) in cash and cash equivalents	4,360,000	-658,000	5,432,000
Cash and cash equivalents at beginning of period	1,072,000	3,549,000	0
Cash and cash equivalents at end of period	5,432,000	2,891,000	5,432,000
Noncash investing and financing activities:	'	'	'
Preferred stock issued in payment of dividend	0	0	61,000
Issuance of common stock for license	0	0	3,405,000
Issuance of common stock, warrant and options in settlement of liabilities, except notes payable	0	0	2,907,000
Notes payable exchanged for common stock	0	0	50,000
Advance settled with common stock	0	0	25,000
Loss on exchange of noncontrolling interest	0	0	232,000
Shares issued for future consulting services	0	0	103,000
Issuance of common stock for a finderbs fee	0	0	225,000
Advance from stockholder	0	0	250,000
Contribution of FTV Ford Truck	0	0	16,000
Ice Engineering LLC payable netted against receivable	0	0	91,000
Common stock issued in settlement of director fee payable	0	0	121,000
Common stock issued in settlement of patent expense	0	0	117,000
Issuance of common stock as payment for Preferred A and B dividends	0	0	207,000
Purchases of fixed assets with debt	0	0	250,000
Purchase of fixed assets from non-monetary exchange	0	0	17,000
Supplemental Disclosures:	'	'	'
Interest paid	1,000	2,000	96,000
Income taxes paid	$0	$0	$1,000

Note_A_The_Company_and_Basis_o

Note A - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	NOTE A — THE COMPANY AND BASIS OF PRESENTATION
	The interim information contained herein with respect to the three month periods ended March 31, 2014 and 2013 and the period from September 25, 1996 (inception) through March 31, 2014 has not been audited but was prepared in conformity with generally accepted accounting principles for interim financial information and instructions for Form 10-Q. Accordingly, the condensed consolidated financial statements do not include all information and footnotes required by generally accepted accounting principles for financial statements. Included are ordinary adjustments which, in the opinion of management, are necessary for a fair presentation of the financial information for the three month periods ended March 31, 2014 and 2013 and since inception. The results are not necessarily indicative of results to be expected for the entire year. Certain amounts in the prior year consolidated financial statements have been reclassified to conform to the current year presentation.
	Torvec, Inc. was incorporated as a New York business corporation on September 25, 1996. Upon its incorporation, the Company acquired numerous patents, inventions and know-how created by Vernon E. Gleasman and his sons, James and Keith Gleasman, a family with more than fifty years of experience in the automotive industry. Since its inception, the Company has endeavored to design, develop, build and commercialize its technology portfolio. We have not yet had any significant revenue-producing operations and, as such, we are a development stage entity. The Company currently is focusing its commercialization strategies on the following technologies: the IsoTorque® differential and the Torvec Hydraulic Pump.
	As used in this quarterly report, unless otherwise indicated, the terms “we”, “our”, “us” and “the Company” refer to Torvec, Inc.

Note_B_Summary_of_Significant_

Note B - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE B — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Consolidation: The financial statements include the accounts of the Company, our wholly-owned subsidiary Iso-Torque Corporation, and our majority-owned subsidiary, Ice Surface Development, Inc. (56% owned at March 31, 2014 and December 31, 2013). As of March 31, 2014, each of the subsidiaries is non-operational. We are intending to let Ice Surface Development, Inc. dissolve by proclamation. All material intercompany transactions and account balances have been eliminated in consolidation.
	Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates are used in valuing the useful lives of any intangible assets and the future realizable value of such assets. These estimates are subject to a high degree of judgment and potential change. Actual results could differ from those estimates.
	Reclassifications: Certain reclassifications have been made to prior year balances to conform to the current year’s presentation.
	Cash and Cash Equivalents: Cash and cash equivalents may include time deposits, certificates of deposit, and highly liquid debt instruments with original maturities of three months or less. We maintain cash and cash equivalents at financial institutions which periodically may exceed federally insured amounts.
	Accounts Receivable: We carry our accounts receivable at invoice amount less an allowance for doubtful accounts.  On a periodic basis, we evaluate our accounts receivable and establish an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions.  We do not accrue interest on past due invoices.  There was $0 allowance for doubtful accounts as of March 31, 2014 and December 31, 2013, as determined by management.
	Inventories: Inventories are stated at the lower of cost or market with cost determined under the first-in, first-out (FIFO) method. We record provisions for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. There was a $24,000 and $26,000 provision for excess, obsolete or slow-moving inventory as of March 31, 2014 and December 31, 2013, respectively, as determined by management.
	Property and Equipment: Property and equipment are stated at cost. Estimated useful lives are as follows:
	Office Equipment and Software (in years)		3-7
	Leasehold Improvements	Lesser of useful life or lease term
	Shop Equipment (in years)		7
	Transportation Equipment (in years)		5-7
	Depreciation and amortization are computed using the straight-line method. Betterments, renewals and extraordinary repairs that extend the life of the assets are capitalized. Other repairs and maintenance costs are expensed when incurred. When disposed, the cost and accumulated depreciation applicable to assets retired are removed from the accounts and the gain or loss on disposition is recognized in other income (expense). Depreciation and amortization expense for the three month periods ended March 31, 2014 and 2013 amounted to $43,000 and $32,000, respectively.
	Whenever events or circumstances indicate, our long-lived assets, including any intangible assets with finite useful lives, are tested for impairment by using the estimated future cash flows directly associated with, and that are expected to arise as a direct result of, the use of the assets. If the carrying amount exceeds the estimated undiscounted cash flows, an impairment may be indicated. The carrying amount is then compared to the estimated discounted cash flows, and if there is an excess, such amount is recorded as an impairment. During the three month periods ended March 31, 2014 and 2013, we recorded $0 in impairment charges.
	Fair Value of Financial Instruments: As defined by U.S. GAAP, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. All assets and liabilities are required to be measured and reported on a fair value basis. A hierarchy for ranking the quality and reliability of the information is used to determine fair values. Assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
	The FASB’s (Financial Accounting Standards Board) guidance for the disclosure about fair value of financial instruments requires disclosure of an estimate of the fair value of certain financial instruments. The fair value of financial instruments pursuant to FASB’s guidance for the disclosure about fair value of financial instruments approximated their carrying values at March 31, 2014 and December 31, 2013. The carrying amount of cash, accounts receivable, accounts payable, and accrued expenses approximates their fair value due to their short maturity. The carrying amount of notes payable approximates fair value because stated or implied interest rates approximate current interest rates that are available for debt with similar terms.
	Revenue Recognition: Our terms provide that customers are obligated to pay for products sold to them within a specified number of days from the date that title to the products is transferred to the customers. Our standard terms are typically net 30 days. We recognize revenue when transfer of title occurs, risk of ownership passes to a customer at the time of shipment or delivery depending on the terms of the agreement with a particular customer and collection is reasonably assured. The sale price of our products is substantially fixed and determinable at the date of the sale based upon purchase orders generated by a customer and accepted by us.
	We occasionally enter into prototype development contracts with customers. In such cases, revenue is recognized using either (a) the proportional effort method based on the relationship of costs incurred to date to the total estimated cost to complete a contract, or (b) where appropriate, the milestone method, if milestones are clearly identifiable and substantive.
	During the first quarter of 2013, we entered into a prototype development agreement with a Chinese automotive manufacturer to design, develop and manufacture an IsoTorque® differential for a specific vehicle application. Essentially, there is one performance milestone associated with the agreement, which is the delivery of our IsoTorque prototypes to the customer that they can test and evaluate. In total, the customer will pay us approximately $39,000 in two installments. We are deferring the recognition of revenue and related expenses pertaining to this development agreement until we achieve the delivery milestone. As of March 31, 2014, we have deferred approximately $20,000 in revenue and approximately $29,000 in expenses associated with this program.
	Research and Development and Patents: Research and development costs and patent expenses are charged to operations as incurred. Research and development includes personnel-related costs, materials and supplies, depreciation, consulting services, and amortization of acquired technology. Depreciation expense for the three month periods ended March 31, 2014 and 2013 that was charged to research and development was $24,000 and $10,000, respectively.
	Patent costs for the three month periods ended March 31, 2014 and 2013 amounted to $32,000 and $45,000, respectively, and are included in general and administrative expenses.
	Stock-based Compensation: FASB Accounting Standards Codification (“ASC”) 718-10 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the service period (generally the vesting period) in the consolidated financial statements based on their fair values on the grant date. Under the modified prospective method that we adopted, awards that were granted, modified, or settled on or after January 1, 2006 are measured and accounted for in accordance with ASC 718-10. Unvested equity-classified awards that were granted prior to January 1, 2006 will continue to be accounted for in accordance with ASC 718-10, except that the grant date fair value of all awards are recognized in the results of operations over the remaining vesting periods. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity in accordance with ASC 718-10.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets. We elected to adopt the alternative method of calculating the historical pool of windfall tax benefits as permitted by ASC 718-10-65 (previously known as: FASB Staff Position (FSP) No. SFAS 123(R)-c, “Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards”). This is a simplified method to determine the pool of windfall tax benefits that is used in determining the tax effects of stock compensation in the results of operations and cash flow reporting for awards that were outstanding as of the adoption of ASC 718-10.
	FASB ASC 505-50, “Equity-Based Payments to Non-Employees,” requires all share-based payments to non-employees, including grants of stock options, to be recognized in the consolidated financial statements as compensation expense generally over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black-Scholes valuation model, we periodically reassess the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and we adjust the expense recognized in the consolidated financial statements accordingly.
	FASB ASC 718-20 requires that modifications of the terms or conditions of equity awards be treated as an exchange of the original award for a new award.  Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified.
	Income Taxes: We account for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of our assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	We account for uncertain tax positions using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax benefits that meet the more-likely-than-not recognition threshold should be measured as the largest amount of tax benefits, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement in the financial statements. It is our policy to recognize interest and penalties related to income tax matters as general and administrative expenses. As of March 31, 2014, there was $0 accrued interest or penalties related to uncertain tax positions. The tax years 2010 through 2013 remain open to examination by the federal and state tax jurisdictions to which we are subject. In addition, our 2009 tax year was examined by the Internal Revenue Service resulting in an inconclusive adjustment due to the expiration of the statute of limitations. Therefore, the Internal Revenue Service will conclude on any findings during a subsequent audit.
	Loss per Common Share: FASB’s ASC 260-10 (previously known as FASB Statement 128, “Earnings Per Share”) requires the presentation of basic earnings per share, which is based on weighted average common stock outstanding, and dilutive earnings per share, which gives effect to options, warrants and convertible securities in periods when they are dilutive. At March 31, 2014 and 2013, we excluded 53,721,662 and 29,108,682 potential common shares, respectively, relating to convertible preferred stock, options and warrants outstanding from the diluted net loss per common share calculation because their inclusion would be anti-dilutive. In addition, we excluded 625,000 warrants from the diluted net loss per common share calculation at March 31, 2014 and 2013 as the conditions for their vesting are not time-based.
	Recent Accounting Pronouncements: In July 2013, FASB issued Accounting Standards Update (“ASU”) 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this standard in the first quarter of 2014 did not have a material impact on the Company’s consolidated financial position and results of operations.

Note_C_Related_Party_Transacti

Note C - Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE C — RELATED PARTY TRANSACTIONS
	[1] On September 14, 2007, we moved our executive offices from Pittsford, New York to Rochester, New York, which includes both a manufacturing and executive office facility. The Rochester facility is owned by a partnership, with which Asher J. Flaum, a Company director, is associated. On April 28, 2008, our board of directors approved the terms of a lease and such lease was executed on April 29, 2008.
	Effective October 24, 2012, we amended certain terms of the lease for our Rochester facility. The primary changes that were made include a two-year extension of the current lease originally set to expire as of May 31, 2013 at the same rent rate, and the addition of two three-year renewal options with a 10% rate increase at each subsequent renewal period. These renewal options replace the previous renewal options of three five-year renewal periods which had incorporated 15% rate increases at each subsequent renewal period. (See Note H[1].)
	[2] On December 13, 2010, we executed a consultant agreement with a director to provide consulting services to us at a rate of $200 per hour. Pursuant to the agreement, we also agreed to pay the consultant an incentive fee equal to $10,000 or proportionate part thereof for each $1,000,000 of revenue or proportionate part thereof actually received by us for a period of five years, provided the definitive agreement with the third party results from the material efforts of the consultant. During each of the three month periods ended March 31, 2014 and 2013, we recorded an expense of $0 for services rendered in relation to this agreement. Cumulatively, through March 31, 2014, we have recorded approximately $3,000 of expense for services rendered in relation to this agreement.
	[3] Effective on March 27, 2012, we hired Dr. William Mark McVea as our Chief Technology Officer. Prior to joining the Company, Dr. McVea provided us with consulting services through KBE+, Inc., a group of consulting engineers engaged in the design and development of gear trains and power transmission devices, and of which Dr. McVea was the principal engineer and president.
	On April 30, 2012, we purchased various test equipment, office furniture, and supplies from KBE+, Inc. for a total of $162,500. We have entered into a financing agreement with KBE+, Inc., whereby we are paying KBE+, Inc. over 24 months in equal monthly installments of approximately $6,800, beginning on May 1, 2012. Based on an imputed interest rate of approximately 5%, the initial principal of the note was approximately $154,000, and as of March 31, 2014, the outstanding principal on the note was approximately $7,000. Interest expense pertaining to this note amounted to approximately $0 and $1,000 for the three month periods ended March 31, 2014 and 2013, respectively.
	In May 2012, we purchased certain additional testing tools and supplies from KBE+, Inc. for approximately $5,700. The outstanding payable to KBE+, Inc. related to this purchase was fully paid during the quarter ended June 30, 2013.
	[4] Effective as of January 1, 2013, we entered into a one-year consulting agreement with SCIRE Corporation, of which one of our directors is president, to provide us with expertise and advice on hydraulic pump technology and related markets. The consulting agreement provided for a guaranteed minimum of $3,840 per month, based on 32 hours of consulting, plus travel costs. On December 4, 2013, we extended this consulting agreement for another year through December 31, 2014, providing for a guaranteed minimum of $2,000 per month, based on 16 hours of consulting, plus travel costs. Additional hours above this minimum in 2014 will be billed at a rate of $125 per hour. During the three month periods ended March 31, 2014 and 2013, we recorded an expense of approximately $7,000 and $13,000, respectively, for consulting services and travel costs related to this agreement.

Note_D_Inventories

Note D - Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	NOTE D — INVENTORIES
	At March 31, 2014 and December 31, 2013, the composition of inventories was:
		March 31,			December 31,
		2014			2013
	Raw Materials	$	24,000		$	26,000
	Finished Goods		13,000			0
	Total Inventories		37,000			26,000
	Reserve for Excess / Obsolete Inventory		(24,000	)		(26,000	)
	Inventories, Net	$	13,000		$	0

Note_E_Accrued_Liabilities

Note E - Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block Supplement [Abstract]	'
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	'
	NOTE E — ACCRUED LIABILITIES
	At March 31, 2014 and December 31, 2013, accrued liabilities consist of the following:
		March 31,		December 31,
		2014		2013
	Accrued Compensation	$	28,000	$	53,000
	Accrued Payroll Taxes Payable		5,000		7,000
	Accrued Legal		12,000		8,000
	Other		24,000		2,000
		$	69,000	$	70,000

Note_F_Notes_Payable

Note F - Notes Payable	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE F — NOTES PAYABLE
	As of March 31, 2014 and December 31, 2013, notes payable consists of the following:
			March 31,2014		December 31,2013
	Copy Machine (1)		$	3,000	$	3,000
	Engineering Design Software (2)			8,000		14,000
	Test Equipment and Supplies (3)			7,000		27,000
	Automobile (4)			9,000		10,000
			$	27,000	$	54,000
		-1	In November 2010, we entered into a capital lease for a copy machine over a 5 year term, with a fair market value buyout. The capitalized value of the lease was approximately $8,900, and the monthly payment is approximately $170 with an implicit interest rate of approximately 5.3%. At December 31, 2013, the outstanding balance on this note was approximately $3,000, of which $2,000 was classified as a non-current liability. At March 31, 2014, the outstanding balance on this note was approximately $3,000, of which $1,000 was classified as a non-current liability.
		-2	In August 2011, we financed the purchase of engineering design software, along with a one-year maintenance agreement, through a three year loan maturing in August 2014, and collateralized by the software. The total cost of the software and the maintenance agreement was approximately $64,800. The monthly payments are approximately $2,100 per month with an implicit interest rate of approximately 9.6%. At December 31, 2013, the outstanding balance on this note was approximately $14,000, which was classified as a current liability. At March 31, 2014, the outstanding balance on this note was approximately $8,000, which was classified as a current liability.
		-3	In April 2012, we financed the purchase of various test equipment, office furniture, and supplies from KBE+, Inc. (of which our chief technology officer is an officer) through a 24 month promissory note for a total amount to be paid of $162,500. Based on an imputed interest rate of approximately 5%, the initial principal of the note was approximately $154,000. The monthly payments are approximately $6,800 per month. At December 31, 2013, the outstanding balance on this related party note was approximately $27,000, which was classified as a current liability. At March 31, 2014, the outstanding balance on this related party note was approximately $7,000, which was classified as a current liability.
		-4	In August 2012, we purchased an automobile for $16,600, a vehicle that we had previously been leasing. We financed this purchase with a 36- month promissory note. The interest rate on the loan is approximately 10%, and the payments are approximately $540 per month. At December 31, 2013, the outstanding balance on this note was approximately $10,000, of which $4,000 was classified as a non-current liability. At March 31, 2014, the outstanding balance on this note was approximately $9,000, of which $3,000 was classified as a non-current liability.

Note_G_Stockholders_Equity

Note G - Stockholders' Equity

3 Months Ended

Mar. 31, 2014

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

NOTE G — STOCKHOLDERS’ EQUITY

[1] Preferred Stock

On August 30, 2000, we amended our certificate of incorporation to permit the Company to issue up to 100,000,000 shares of $0.01 par value preferred stock. Under the amendment, the board of directors has the authority to allocate these shares into as many separate classes of preferred as it deems appropriate and with respect to each class, designate the number of preferred shares issuable and the relative rights, preferences, seniority with respect to other classes and to our common stock and any limitations and/or restrictions that may be applicable without obtaining shareholder approval.

(a)  Class A Preferred Stock

In 2002, our board designated the first series of preferred shares, authorizing the issuance of up to 3,300,000 Class A Non-Voting Cumulative Convertible Preferred Shares. Each Class A Preferred Share is convertible after a one year holding period, at the holder’s election, into one share of our common stock. The conversion rate is subject to adjustment in the event of the issuance of our common stock as a dividend or distribution and in the case of the subdivision or combination of our common stock. The Class A Preferred has no voting rights, except with respect to matters directly impacting upon the rights and privileges accorded to such Class.

The holders of the Class A Preferred are entitled to receive cumulative preferential dividends in the amount of $0.40 per share of Class A Preferred for each annual dividend period.

Dividends payable on the Class A Preferred will be paid in cash out of any funds legally available for the payment of dividends or, in the discretion of the board, will be paid in Class A Preferred at a rate of 1 share of Class A Preferred for each $4.00 of dividends.

If dividends are paid in shares of Class A Preferred, such dividend shares are not entitled to accumulate additional dividends and themselves may be converted into the common stock of the Company on a one for one basis. Holders of Class A Preferred are permitted to request that dividends payable in Class A Preferred be immediately converted into shares of our common stock. At times, our board may elect to settle the dividends through the issuance of common stock in lieu of cash.

Accumulated and unpaid dividends on the Class A Preferred will not bear interest. Class A Preferred shares are also entitled to participate pro rata in dividends declared and/or distributions made with respect to all classes of our outstanding equity.

We may, in the absolute discretion of our board, redeem at any time and from time to time from any source of funds legally available any and all of the outstanding Class A Preferred at the redemption price of $4.00 per Class A Preferred, plus all unpaid accumulated dividends payable with respect to each Class A Preferred Share.

Since its designation in March 2002, we have sold an aggregate 765,512 shares of Class A Preferred for proceeds of approximately $3,062,000. No Class A Preferred shares were sold during the three month period ended March 31, 2014 and the year ended December 31, 2013.

Since its designation in March 2002, Class A Preferred shareholders have converted an aggregate 189,750 Class A Preferred into our common stock (on a one to one basis) through March 31, 2014. There were 0 Class A Preferred shares converted in each of the three month periods ended March 31, 2014 and 2013.

For each of the three month periods ended March 31, 2014 and 2013, we settled 0 Class A Preferred dividends. Since its inception in March 2002 through March 31, 2014, we have settled an aggregate Class A Preferred dividend amounting to approximately $242,000 through the issuance of 11,339 Class A Preferred shares and 100,924 common shares.

At March 31, 2014, there were 587,101 outstanding shares of Class A Preferred stock, of which 11,339 shares resulted from the settlement of dividends due to conversion, and those shares no longer accrue dividends. The value of dividends payable upon the conversion of the remaining 575,762 outstanding shares of Class A Preferred stock amounted to approximately $2,076,000 at March 31, 2014, of which $58,000 was accrued during the three month period ended March 31, 2014.

In the event of the liquidation, dissolution and winding up of the Company, and subject to the liquidation rights and privileges of our Class C Preferred, Class A Preferred shareholders have a liquidation preference with respect to all accumulated and unsettled dividends. The value of the Class A Preferred shareholders’ liquidation preference was approximately $2,076,000 and $2,019,000 at March 31, 2014 and December 31, 2013, respectively. In the event of a liquidation, dissolution or winding up of the Company, unpaid accumulated dividends on the Class A Preferred are payable in Class A Preferred shares at a rate of 1 share of Class A Preferred for each $4.00 of dividends.

(b)  Class B Preferred Stock

In September 2004, the board created a second series of preferred stock by authorizing the issuance of up to 300,000 Class B Non-Voting, Cumulative Convertible Preferred Shares to fund the business operations of Iso-Torque Corporation, an entity incorporated to separately commercialize our IsoTorque differential technology.

Each Class B Preferred Share is convertible after a one year holding period, at the holder’s election, into one share of our common stock or one share of the common stock of IsoTorque Corporation. The conversion rate is subject to adjustment in the event of the issuance of the Company’s or IsoTorque Corporation’s common stock as a dividend or distribution and in the case of the subdivision or combination of such common stock. The Class B Preferred has no voting rights, except with respect to matters directly impacting upon the rights and privileges accorded to such Class.

Subject to the dividend rights and privileges of our Class A Preferred, the holders of the Class B Preferred are entitled to receive cumulative preferential dividends in the amount of $0.50 per share of Class B Preferred for each annual dividend period.

Dividends payable on the Class B Preferred will be paid in cash out of any funds legally available for the payment of dividends or, in the discretion of the board, will be paid in Class B Preferred at a rate of 1 share of Class B Preferred for each $5.00 of dividends.

If dividends are paid in shares of Class B Preferred, such dividend shares are not entitled to accumulate additional dividends and themselves may be converted into the common stock of the Company on a one for one basis. Holders of Class B Preferred are permitted to request that dividends payable in Class B Preferred be immediately converted into shares of our common stock.

Accumulated and unpaid dividends on the Class B Preferred will not bear interest. Class B Preferred shares are also entitled to participate pro rata in dividends declared and/or distributions made with respect to all classes of our outstanding equity.

We may, in the absolute discretion of our board, redeem at any time and from time to time from any source of funds legally available any and all of the outstanding Class B Preferred at the redemption price of $5.00 per Class B Preferred, plus all unpaid accumulated dividends payable with respect to each Class B Preferred Share.

Since its designation in September 2004, we have sold an aggregate 97,500 Class B Preferred in a number of private placements for proceeds of approximately $487,500. No Class B Preferred shares were sold during the three month period ended March 31, 2014 and the year ended December 31, 2013.

Since its designation, Class B Preferred shareholders have converted an aggregate 30,000 Class B Preferred into our common stock (on a one to one basis) through March 31, 2014. Through March 31, 2014, no Class B Preferred shares have been issued to converting Class B Preferred shareholders as a dividend.

Depending upon our cash position, from time to time we may request that a converting preferred shareholder receiving dividends in cash consent to receive shares of restricted common stock in lieu thereof. During the three month periods ended March 31, 2014 and 2013, we settled 0 Class B Preferred dividends. Cumulatively through March 31, 2014, we have issued 35,431 restricted common shares in payment of Class B dividends amounting to approximately $51,000.

At March 31, 2014, dividends payable upon the conversion of 67,500 outstanding shares of Class B Preferred amounted to approximately $294,000, of which $8,000 was accrued during the three month period ended March 31, 2014. In the event of the liquidation, dissolution and winding up of the Company, and subject to the liquidation rights and privileges of our Class C Preferred and our Class A Preferred, Class B Preferred shareholders have a liquidation preference with respect to all accumulated and unsettled dividends. The value of the Class B Preferred shareholders’ liquidation preference was $294,000 and $285,000 at March 31, 2014 and December 31, 2013, respectively. In the event of a liquidation, dissolution or winding up of the Company, unpaid accumulated dividends on the Class B Preferred are payable in Class B Preferred shares at a rate of 1 share of Class B Preferred for each $5.00 of dividends.

(c)  Series C Preferred Stock

In September 2011, the board of directors authorized, and Class A Preferred and Class B Preferred shareholders approved, a third series of preferred stock, namely 16,250,000 shares of Series C Voting Convertible Preferred Stock. On September 23, 2011, we sold and issued a total of 16,250,000 shares of Series C Voting Convertible Preferred Stock and warrants to purchase 1,625,000 shares of our common stock in a private placement transaction, generating gross proceeds of $6,500,000. Direct expenses of approximately $106,000 pertaining to the transaction, consisting of primarily external legal costs, were incurred, resulting in net proceeds of approximately $6,394,000.

Each Series C Preferred share is convertible, at the holder’s election, into one share of our common stock. The conversion rate is subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock.

The Series C Preferred shares have a liquidation preference at their stated value per share of $0.40 that is senior to our common stock, and the Company’s Class A Non-Voting Cumulative Convertible Preferred Shares and Class B Non-Voting Cumulative Convertible Preferred Shares. The liquidation preference is payable upon a liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or upon a deemed liquidation of the Company.

The Series C Preferred shares have no right to receive dividends and have no redemption right. The Series C Preferred shares vote with the common stock on an as-converted basis.

The associated warrants have a ten (10) year term and are immediately exercisable for 1,625,000 shares of common stock. The warrants are exercisable, at the holder’s election, for shares of the Company’s common stock in either a cash or cashless exercise. The warrants have an exercise price equal to the greater of (i) $0.01 or (ii) eighty percent (80%) of the volume weighted average sale price per share of our common stock during the ten (10) consecutive trading days immediately preceding the notice of exercise. The number of warrants and exercise price are subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock. At the time of issuance, we estimated a value of $0.50 per warrant, or a total of approximately $812,000, using a weighted average of assigned probabilities for various gain scenarios at certain price points based on expected volatility. As a result of the combined issuance of the Series C Preferred stock with the associated warrants, we reflected a non-cash distribution on the Series C Preferred shares for the warrants issued in our consolidated statements of operations for 2011. (See Note G[3](o).)

In conjunction with the issuance of the 16,250,000 shares of Series C Preferred stock, we computed the value of the non-cash beneficial conversion feature associated with the right to convert the shares into common stock on a one-for-one basis. We compared the fair value of our common stock on the date of issuance with the effective conversion price after allocation of the proceeds to the related warrants, and determined that the value of the non-cash beneficial conversion feature is approximately $5,582,000, which was reflected in our consolidated statements of operations for the year ended December 31, 2011 as an adjustment to arrive at the net loss attributable to common stockholders.

Cumulatively through March 31, 2014, Series C Preferred shareholders have converted 0 shares of Series C Preferred into common stock. At March 31, 2014, there were 16,250,000 shares of Series C Preferred stock outstanding. The value of the Series C Preferred shareholders’ liquidation preference was $6,500,000 at March 31, 2014.

(d)  Series C-2 Preferred Stock

In March 2014, the board of directors authorized, and Class A Preferred, Class B Preferred and Series C Preferred shareholders approved, a third series of preferred stock, namely 25,000,000 shares of Series C-2 Voting Convertible Preferred Stock. On March 28, 2014, we sold and issued a total of 25,000,000 shares of Series C-2 Voting Convertible Preferred Stock in a private placement transaction, generating gross proceeds of $5,000,000. Direct expenses of approximately $46,000 pertaining to the transaction, consisting of primarily external legal costs, were incurred, resulting in net proceeds of approximately $4,954,000.

Each Series C-2 Preferred Share is convertible, at the holder’s election, into one share of our common stock, par value $0.01 per share. The conversion rate is subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock or a reorganization, recapitalization, reclassification, consolidation or merger of the Company.

The Series C-2 Preferred Shares have a liquidation preference at their stated value per share of $0.20 that ranks pari passu to our existing Series C Voting Convertible Preferred Shares and is senior to our common stock, and our Class A Non-Voting Cumulative Convertible Preferred Shares and Class B Non-Voting Cumulative Convertible Preferred Shares. The liquidation preference is payable upon a liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or upon a deemed liquidation of the Company. A deemed liquidation includes, unless decided by the holders of at least two-thirds of the Series C-2 Preferred Shares, any consolidation, merger, or reorganization of the Company in which the shareholders of the Company own less than fifty percent of the voting power of the resultant entity, or an acquisition to which the Company is a party in which at least fifty percent of the Company’s voting power is transferred, or the sale, lease, exclusive license or transfer of all or substantially all of the assets or intellectual property of the Company other than to a wholly owned subsidiary.

The Series C-2 Preferred Shares are not entitled to receive preferred dividends and have no redemption right, but are entitled to participate, on an as converted basis, with holders of outstanding shares of common stock in dividends and distributions on liquidation after all preferred shares have received payment in full of any preferred dividends or liquidation preferences. The Series C-2 Preferred Shares vote with the common stock on an as-converted basis. We may not, without approval of the holders of at least two-thirds of the Series C-2 Preferred Shares, (i) create any class or series of stock that is pari passu or senior to the Series C-2 Preferred Shares; (ii) create any class or series of stock that would share in the liquidation preference of the Series C-2 Preferred Shares or that is entitled to dividends payable other than in common stock or Series C-2 Preferred Shares of its own series, (iii) acquire any equity security or pay any dividend, except dividends on a class or series of stock that is junior to the Series C Preferred Shares, payable in such junior stock, (iv) reissue any Series C-2 Preferred Shares, (v) declare or pay any dividend that would impair the payment of the liquidation preference of the Series C-2 Preferred Shares, (vi) authorize or issue any additional Preferred Shares, (vii) change the Certificate of Incorporation to adversely affect the rights of the holders of the Series C-2 Preferred Shares, or (viii) authorize, commit to or consummate any liquidation, dissolution or winding up in which the liquidation preference of the Series C-2 Preferred Shares would not be paid in full.

Pursuant to the transaction, we must within 180 days, use commercially reasonable efforts to raise $1,000,000, in a separate private placement or private placements, through the offer and sale of an additional Series C-3 Voting Convertible Preferred Stock, par value $0.01 per share (the “Series C-3 Preferred Shares”). The Series C-3 Preferred Shares, if and when created, will rank pari passu with the existing Series C Voting Convertible Preferred Shares and the Series C-2 Preferred Shares, and have a senior preference in liquidation or deemed liquidation over the Company’s outstanding shares of common stock, and Class A and Class B Preferred stock. The Series C-3 Preferred Shares would be convertible on a one-to-one basis into shares of common stock (subject to adjustment) without payment of any additional consideration. The Series C-3 Preferred Shares would not be entitled to preferred dividends, but similar to the Series C-2 Preferred Shares, would be entitled to participate, on as converted basis, with shares of common stock in dividends and distributions on liquidation after all preferred shares have received payment in full of any preferred dividends or liquidation preferences, have such other customary rights, privileges, preferences and limitations. The pricing of the Series C-3 Preferred Shares will be determined by the Board of Directors prior to the initial closing of the sale of those shares.

We plan to conduct the sale of the Series C-3 Preferred Shares sometime in the near future. The Series C-2 Preferred Shares, and the Series C-3 Preferred Shares to be sold will not be and have not been registered under the Securities Act of 1933, as amended, or the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. There can be no assurance that we will be successful in raising any needed amounts on these terms for these uses or that these amounts will be sufficient for our plans.

In conjunction with the issuance of the 25,000,000 shares of Series C-2 Preferred stock, we computed the value of the non-cash beneficial conversion feature associated with the right to convert the shares into common stock on a one-for-one basis. We compared the fair value of our common stock on the date of issuance with the effective conversion price, and determined that the value of the non-cash beneficial conversion feature is approximately $4,250,000, which is reflected in our condensed consolidated statements of operations for the three month period ended March 31, 2014 as an adjustment to arrive at the net loss attributable to common stockholders.

Cumulatively through March 31, 2014, Series C-2 Preferred shareholders have converted 0 shares of Series C-2 Preferred into common stock. At March 31, 2014, there were 25,000,000 shares of Preferred C-2 stock outstanding. The value of the Series C-2 Preferred shareholders’ liquidation preference was $5,000,000 at March 31, 2014.

[2] Stock Options

(a)  1998 Stock Option Plan

In December 1997, our board approved a Stock Option Plan (the “1998 Plan”) which provided for the granting of up to 2,000,000 shares of common stock, pursuant to which officers, directors, key employees and key consultants/advisors are eligible to receive incentive, nonqualified or reload stock options which plan was ratified by the shareholders on May 28, 1998. Options granted under the 1998 Plan are exercisable for a period of up to 10 years from date of grant at an exercise price which is not less than the fair value on date of grant, except that the exercise period of options granted to a stockholder owning more than 10% of the outstanding capital stock may not exceed five years and their exercise price may not be less than 110% of the fair value of the common stock at date of grant. Options may vest over five years.

By its terms, our 1998 Plan terminated as to the grant of future options on May 27, 2008. Consequently, no additional stock options will be granted under the 1998 Plan, although outstanding options remain available for exercise in accordance with their terms. There were 0 options exercised under the 1998 Plan during each of the three month periods ended March 31, 2014 and 2013.

Through March 31, 2014, a total of 1,823,895 stock options had been granted under the 1998 Plan and 0 stock options had been exercised. During each of the three month periods ended March 31, 2014 and 2013, 0 stock options expired. Since the plan’s inception, a total of 1,723,895 stock options have expired. As of March 31, 2014, there were 100,000 outstanding stock options under the 1998 Plan, all of which were fully vested. As of March 31, 2014, we had $0 unrecognized stock compensation related to unvested awards under the 1998 Plan.

(b)  2011 Stock Option Plan

On November 3, 2010, the board adopted, and on January 27, 2011 the shareholders approved, the 2011 Stock Option Plan (“2011 Plan”) which provides for the grant of up to 3,000,000 common stock options to provide equity incentives to directors, officers, employees and consultants. Two types of options may be granted under the 2011 Plan: non-qualified options and incentive options.

Non-qualified options may be granted to our officers, directors, employees and outside consultants. Incentive options may be granted only to our employees, including officers and directors who are also employees. In the case of non-qualified options, the exercise price may be less than the fair market value of our stock on the date of grant. In the case of incentive options, the exercise price may not be less than such fair market value and in the case of an employee who owns more than 10% of our common stock, the exercise price may not be less than 110% of such market price. Options generally are exercisable for ten years from the date of grant, except that the exercise period for an incentive option granted to an employee who owns more than 10% of our stock may not be greater than five years.

Effective January 22, 2014, General Wesley K. Clark, one of our board members, tendered his resignation as a voting member of the Company’s board of directors due to personal reasons. In order to continue to support the Company, Gen. Clark agreed to accept a role as a non-voting special advisor to the board. In connection with this event, the board approved a modification to Gen. Clark’s stock option agreement for 250,000 options (as initially granted on January 28, 2011 and subsequently amended on March 20, 2012), to allow for his stock options to remain intact in his new role as special advisor to the board. As of January 22, 2014, Gen. Clark is considered a non-employee for purposes of determining expense associated with stock compensation, and as such the expense reflected on our condensed consolidated statement of operations will fluctuate based on fair value in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees.” During the first quarter of 2014, we recognized a credit adjustment to expense of approximately $109,000 as a result of the impact from this modification. Fair value was determined based on updated valuation assumptions for the options using the Black-Scholes valuation model as of the applicable measurement date. The period over which the remaining amount of unrecognized expense of approximately $15,000 will be recognized will be related to Gen. Clark’s requisite service period for the unvested tranches of the options, which is concurrent with the vesting dates of the remaining unvested tranches of the options.

In August 2013, we granted an incentive stock option to an existing employee to acquire 25,000 common shares at an exercise price of $0.45 per share, exercisable for 10 years. The option vests in four tranches of 25% of the total granted shares on each of the four annual anniversary dates from the initial date of grant.

In November 2013, we granted a non-qualified stock option to our chairman of the board to acquire 100,000 common shares at an exercise price of $0.36 per share, exercisable for 10 years. This grant relates to the chairman’s services as a director and replaced a previously issued option that had recently expired by its terms. The option vests in four tranches of 25% of the total granted shares on each of the four annual anniversary dates from the initial date of grant.

In February 2014, we granted an incentive stock option to an existing employee to acquire 500 common shares at an exercise price of $0.34 per share, exercisable for 10 years. The option vests in four tranches of 25% of the total granted shares on each of the four annual anniversary dates from the initial date of grant.

During the three month period ended March 31, 2014, we granted 500 stock options under the 2011 Plan, 125,250 options became vested, and 0 options expired or were exercised. During the three month period ended March 31, 2013, we granted 0 stock options under the 2011 Plan, 125,250 options became vested, and 0 options expired or were exercised. As of March 31, 2014, there were 1,307,500 stock options outstanding under the 2011 Plan, 670,996 of which were vested. At March 31, 2014, there were 1,692,500 options remaining available for future grant under the 2011 Plan.

(c)  Non-Plan Options

As of March 31, 2014, there were a total of 7,063,336 non-plan options outstanding, of which 4,575,836 were fully vested. During each of the three month periods ended March 31, 2014 and 2013, we granted 0 non-plan stock options, 337,500 options became vested, and 0 options were exercised or cancelled.

(d)  Summary

For the three month periods ended March 31, 2014 and 2013, compensation cost related to all stock options amounted to $13,000 and $229,000, respectively. As of March 31, 2014, there was approximately $497,000 of total unrecognized compensation costs related to outstanding stock options, which are expected to be recognized over the next 3.9 years, of which approximately $16,000 is subject to non-employee mark-to-market adjustments.

During the three month period ended March 31, 2014 , we granted 500 stock options with a weighted average grant-date fair value of $0.34. During the three month period ended March 31, 2013, we granted 0 stock options. The total grant date fair value of all stock options vested during the three month periods ended March 31, 2014 and 2013 was approximately $688,000 and $680,000, respectively.

The fair value of each option granted during the three month period ended March 31, 2014 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions (no options were granted during the three month period ended March 31, 2013):

2014

Expected Term (in years)

6.3

Expected forfeiture rate

0

%

Risk-free rate

1.9

%

Volatility

134.3

%

Dividend yield

0

%

The average risk-free interest rate is based on the U.S. treasury security rate in effect as of the grant date. We determined expected volatility using the historical closing stock price. The expected term was generally determined using the simplified method as we do not believe we have sufficient historical stock option exercise experience on which to base the expected term.

The following summarizes the activity of all of our outstanding stock options for the three month period ended March 31, 2014:

Shares

Weighted

Weighted

Aggregate

Average

Average

Intrinsic

Exercise

Remaining

Value

Price

Contractual

Term (in years)

Outstanding at January 1, 2014

8,470,336

(A)

$

0.69

Granted

500

0.34

Exercised

0

0

Canceled or expired

0

0

Outstanding at March 31, 2014

8,470,836

(A)

$

0.69

6.6

$

315,000

Exercisable at March 31, 2014

5,346,832

$

0.81

6.5

$

180,000

Note (A) – Figures include the impact of 405,000 options that were granted in 2011 to replace options / warrants previously granted to certain engineering personnel. The previously issued options / warrants will expire as the newer options vest on a one-to-one basis. During the fourth quarter of 2012, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011. Again during 2013, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011 options. As of March 31, 2014, there are 135,004 of the 2011 options remaining to vest.

As of March 31, 2014, the exercise prices of all outstanding stock options, as well as all vested stock options, ranged from $0.34 per share to $5.00 per share.

[3] Warrants

As of March 31, 2014, outstanding warrants to acquire shares of our common stock are as follows:

Exercise

Expiration

Number of Warrants

Number of

Price

Outstanding

Warrants

Exercisable

Not yet determinable

Not yet determinable

125,000

(a)

0

$

0.75

None

500,000

(b)

0

$

0.01

2015-2016

54,500

(c)

54,500

$

0.01

None

3,000

(d)

3,000

$

5

None

55,000

(e)

55,000

$

5

2016

66,668

(e)

66,668

$

0.01

None

60,000

(f)

60,000

$

0.01

2016

3,750

(g)

3,750

$

1

None

20,500

(h)

20,500

$

0.44

2020

400,000

(i)

400,000

$

3.75

2016

200,000

(j)

200,000

$

5

2016

30,000

(k)

30,000

$

5

2017

50,000

(l)

50,000

$

5

2017

100,000

(m)

100,000

$

2.5

2020

100,000

(n)

100,000

Not yet determinable

2021

1,625,000

0

1,625,000

3,393,418

2,768,418

(a)

Exercisable only if we have an IPO and exercisable at the IPO price five years from IPO. Through March 31, 2014, we have not conducted an IPO.

(b)

On April 15, 2002, we issued 1,000,000 warrants at prices ranging from $0.30 to $0.75 to our then chairman of the board of directors and chief executive officer. Of the total warrants, 250,000 were exercisable at $0.30, and 250,000 were exercisable at $0.50 on the date the then board elected the executive to the board and named him chief executive officer. During the year ended December 31, 2002, 250,000 warrants were exercised for $0.30 per share, resulting in proceeds of $75,000. During the year ended December 31, 2003, 250,000 warrants were exercised for $0.50 per share, resulting in proceeds of $125,000. The remaining 500,000 warrants are exercisable upon the occurrence of a significant transaction, which includes execution by us of a binding agreement for the sale, transfer, license or assignment for value of any and/or all of our automotive technology, at $0.75 per share. We will record a charge representing the fair value of the warrants when the warrants become exercisable.

(c)

We issued an aggregate 123,500 warrants at an exercise price of $0.01 with a ten year term to our nonmanagement directors for services rendered to the board under our Nonmanagement Directors Plan prior to its amendment on October 13, 2006. There are 0 further warrants issuable under the Plan as modified by the board of directors on October 13, 2006. An aggregate 69,000 warrants have been exercised for proceeds of $690.

(d)

In 2005, we issued 12,500 warrants to consultants, immediately exercisable at $0.01 per common share. During 2005 and 2006, 3,500 of these warrants were exercised. During 2010, an additional 6,000 of these warrants were exercised. The 3,000 remaining outstanding warrants have no expiration date.

(e)

In 2005, we issued 95,000 warrants to two engineering and administrative consultants, exercisable immediately at $5.00 per common share. During 2006, we issued an additional 100,000 warrants to these same consultants exercisable over a ten year term at $5.00 per common share, but only exercisable if there is a commercializing event as determined by the board of directors. During 2008, these warrants were cancelled and new warrants were issued to the same consultants for an aggregate 195,000 shares exercisable until 2016 at $5.00 per common share and conditioned upon the happening of a commercializing event as determined by the board. We recorded a charge of $249,000 in 2008 to general and administrative expense. In 2010, 95,000 of the total number of 195,000 warrants issued to these consultants were modified to eliminate both the term and the commercializing event condition for exercise. The charge related to the 2010 modification was insignificant. In December 2011, 110,000 of these outstanding warrants were amended so that they will be cancelled in conjunction with the vesting of stock options that were issued to replace such warrants, with each option having an exercise price of $1.14 per share, and proportionate vesting on each of the succeeding anniversary dates over a three year period. The approximately $16,000 expense related to the issuance of the stock options to replace the warrants is being amortized over the vesting period of the stock options. In the fourth quarter of 2012, 36,666 of these warrants were cancelled as the corresponding number of options vested. In the fourth quarter of 2013, another 36,666 of these warrants were cancelled as the corresponding number of options vested.

(f)

During 2005, we issued 60,000 warrants to an engineering consultant exercisable immediately at $5.00 per common share and with no expiration date.

(g)

During 2005, we issued 62,500 warrants to investors in connection with their purchase of 62,500 Class A Preferred, immediately exercisable at $0.01 per common share and with a ten year term. During 2006, we issued 135,849 warrants to investors along with their purchase of 162,000 Class A Preferred and 20,000 Class B Preferred, all immediately exercisable at $0.01 per common share and with a ten year term. Through March 31, 2014, an aggregate of 194,599 of these warrants have been exercised for proceeds of approximately $1,258. There were 0 warrants exercised during the three month period ended March 31, 2014.

(h)

During 2006, one investor purchased 20,500 warrants with no expiration date and an exercise price of $1.00 per common share, for a purchase price of $2,000.

(i)

During 2006, we issued 400,000 warrants immediately exercisable for ten years at an exercise price of $3.27 per common share to a business consultant. Effective October 15, 2010, these warrants were modified and reissued upon the mutual agreement of the parties. Effective October 15, 2010, we issued 400,000 warrants immediately exercisable at $0.44 per common share for a period of ten years from the modification date. As a result of the modification, we recorded a charge of $68,000 to general and administrative expenses in the fourth quarter of 2010. During the three month period ended March 31, 2014, 0 warrants were exercised.

(j)

During 2006, we issued 200,000 warrants immediately exercisable for ten years at an exercise price of $3.75 per common share to a former governmental affairs consultant.

(k)

In 2006, we issued 30,000 warrants to consultants exercisable immediately for a ten year term at $5.00 per common share.

(l)

During 2007, we issued 50,000 warrants exercisable for ten years at $5.00 per common share upon the happening of a commercializing event. The warrants were issued to a consultant who assisted us to potentially place our products in various state school bus programs. We recorded a charge of $249,000 to general and administrative expenses.

(m)

During 2007, we issued 100,000 warrants immediately exercisable for ten years at an exercise price of $5.00 per common share to two engineering consultants in connection with our engagement to furnish constant velocity joints to a military contractor. We recorded a charge of $401,000 to general and administrative expenses.

(n)

On February 17, 2010, we issued 100,000 common stock warrants exercisable for ten years at an exercise price of $2.50 per common share to an adviser. We recorded a charge of $45,000 to general and administrative expenses in the first quarter of 2010.

(o)

On September 23, 2011, we issued 1,625,000 common stock warrants in connection with the sale and issuance of a total of 16,250,000 shares of Series C Voting Convertible Preferred Stock in a private placement transaction, generating gross proceeds of $6,500,000. The warrants have a ten (10) year term and are immediately exercisable for 1,625,000 shares of common stock. The warrants are exercisable, at the holder’s election, for shares of our common stock in either a cash or cashless exercise. The warrants have an exercise price equal to the greater of (i) $0.01 or (ii) eighty percent (80%) of the volume weighted average sale price per share of our common stock during the ten (10) consecutive trading days immediately preceding the notice of exercise. The number of warrants and exercise price are subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock. (See Note G[1](c).)

We typically use the Black-Scholes option-pricing model to estimate the fair value of stock-based awards. However, for the 1,625,000 warrants issued in September 2011, the exercise price is variable based on 80% of the price of our common stock on the date of exercise. For the valuation of these particular warrants, we used a weighted average of assigned probabilities for various gain scenarios at certain price points based on expected volatility of approximately 136% over an assumed term of five years to estimate an overall value of these warrants, which amounted to approximately $812,000, or $0.50 per warrant. These inputs are unobservable inputs based on our own assumptions used to measure the value of the instrument. Accordingly, these warrants are classified within Level 3 of the fair value hierarchy in accordance with FASB ASC 820.

The following summarizes the activity of our outstanding warrants for the three month period ended March 31, 2014:

Shares

Weighted

Weighted

Aggregate

Average

Average

Intrinsic

Exercise

Remaining

Value

Price

Contractual

Term (in years)

Outstanding at January 1, 2014

3,393,418

$

2.06

(A)

Granted

0

0

Exercised

0

0

Canceled or expired

0

0

Outstanding at March 31, 2014

3,393,418

$

2.06

(A)

6.3

(B)

$

162,000

Exercisable at March 31, 2014

2,768,418

$

2.63

6.3

(C)

$

162,000

(A)

The weighted average exercise price for warrants outstanding as of January 1, 2014 and March 31, 2014 excludes 1,750,000 warrants with no determined exercise price.

(B)

The weighted average remaining contractual term for warrants outstanding as of March 31, 2014 excludes 763,500 warrants with no expiration date.

(C)

The weighted average remaining contractual term for warrants exercisable as of March 31, 2014 excludes 138,500 warrants with no expiration date.

Note_H_Commitments_and_Other_M

Note H - Commitments and Other Matters	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE H — COMMITMENTS AND OTHER MATTERS
	[1] Leases
	We lease a facility from a related party (see Note C[1]) located at 1999 Mount Read Blvd., Rochester, New York. The lease expires on May 31, 2015, providing for rent to be paid at a rate of $5,687 per month ($68,244 per annum) and in addition, for the payment of our proportionate share of yearly real estate taxes and yearly common area operating costs. The lease includes two three-year renewal options with a 10% rate increase at each subsequent renewal period.
	Rent expense for each of the three month periods ended March 31, 2014 and 2013 was approximately $17,000. Rent payments required under the amended lease for the full years ending December 31, 2014 and 2015, excluding consideration for any renewal option periods, amount to approximately $68,000 and $28,000, respectively.
	[2] Employment Agreements
	Effective October 4, 2010, we appointed a new chief executive officer and executed a five year employment agreement pursuant to which we will pay base compensation of $50,000 per annum, which compensation increases to $200,000 per annum on the first day of the calendar year immediately following the calendar year in which we have adjusted EBITDA of at least $300,000 (earnings before interest, taxes, depreciation and amortization, but excluding all non-cash expenses associated with stock options). Under the agreement, the executive is entitled to a performance bonus based upon financial targets established each year in good faith by the Governance and Compensation Committee and the achievement of individual management objectives established annually by such committee. The executive is entitled to participate in all employee benefit plans as are provided from time to time for senior executives. If we terminate the executive, remove him as CEO, or a change in control of the Company occurs, the executive is entitled to three years’ severance pay, consisting of base pay and any incentive compensation.
	Effective October 18, 2010, we engaged a new chief financial officer under a letter agreement dated October 18, 2010. If we terminate the executive, remove him as CFO, or a change in control of the company occurs, the executive is entitled to 12 months’ severance pay.
	[3] Consulting Agreements
	Effective July 1, 2010, in two separate agreements, we engaged the services of a consulting firm to provide expertise with business development initiatives, strategic planning and general funding opportunities. We agreed to pay the consultant an annual retainer of $82,500 for both agreements combined, to be paid in quarterly installments. We also agreed to pay the consultant a commission equal to 4% of the value received by us from third parties introduced by or through the auspices of the consultant for a period of a minimum of 4 years beyond the initial term of the agreement. The agreements were for one and two year terms. On March 31, 2011, we signed a modification agreement pursuant to which, in exchange for a one-time payment of $17,250, all of the cash obligations under these two agreements were cancelled. The obligation to pay a 4% commission with respect to the generation of business from efforts initiated by the consultant remains in effect through January 1, 2017.
	On December 13, 2010, we executed a three-year consultant agreement with a director to provide consulting services to us at a rate of $200 per hour. Pursuant to the agreement, we also agreed to pay the consultant an incentive fee equal to $10,000 or proportionate part thereof for each $1,000,000 of revenue or proportionate part thereof actually received by us for a period of five years, provided the definitive agreement with the third party results from the material efforts of the consultant. In December 2013, the agreement was automatically renewed for an additional three years through December 13, 2016. During each of the three month periods ended March 31, 2014 and 2013, we recorded an expense of $0 for consulting services under the agreement. Cumulatively, through March 31, 2014, we have recorded approximately $3,000 of expense for services rendered in relation to this agreement.
	Effective as of January 1, 2013, we entered into a one-year consulting agreement with SCIRE Corporation, of which one of our directors is president, to provide us with expertise and advice on hydraulic pump technology and related markets. The consulting agreement provides for a guaranteed minimum of $3,840 per month, based on 32 hours of consulting, plus travel costs. On December 4, 2013, we extended this consulting agreement for another year through December 31, 2014, providing for a guaranteed minimum of $2,000 per month, based on 16 hours of consulting, plus travel costs. Additional hours above this minimum in 2014 will be billed at a rate of $125 per hour. During the three month periods ended March 31, 2014 and 2013, we recorded an expense of approximately $7,000 and $12,000, respectively, for consulting services and travel costs related to this agreement.
	[4] Prototype Development Agreements
	On January 28, 2011, we announced that we entered into a contract with a West Virginia remanufacturer of components for the mining and associated industrial equipment industry to develop, evaluate, manufacture and sell our IsoTorque® differential technology in mining shuttle cars. The contract calls for us to design and build a prototype IsoTorque® unit for installation in a 21 SC model mining shuttle car. The remanufacturer will pay us $120,000 for the initial development. Upon successful completion of the prototype phase, the parties have agreed that we will sell 100% of the differential requirements for all 21 SC model mining shuttle cars remanufactured by the remanufacturer on an exclusive basis. Minimum purchase requirements were to be established after the first anniversary of the agreement. Through March 31, 2014, we have recorded a total of $90,000 in revenue associated with this agreement.
	In January 2013, after many months of discussions, we entered into a development agreement with Chinese automotive manufacturer, BAIC Motor Co., Ltd. (“BAIC”). Under the agreement, BAIC will pay us to manufacture a number of prototypes of our IsoTorque® differential for one of BAIC’s anticipated future car models. We will supply BAIC with these prototypes for its evaluation and testing. During the third quarter of 2013, we received an initial cash deposit of approximately $20,000 along with initial documentation and hardware, and we have begun the development work on this project. The total value of this development project is approximately $39,000 with a timetable for completion of our work of 25 weeks from the date we received all items specified from BAIC. Since there essentially is one performance milestone associated with this agreement, we have deferred the recognition of revenue and related expenses on this project until we have delivered the prototype units at the completion of the current development agreement. The initial $20,000 deposit we received is reflected as deferred revenue on the condensed consolidated balance sheet as of March 31, 2014. Similarly, we have deferred approximately $29,000 in expenses related to this contract, and these costs are reflected in prepaid expenses and other current assets on the condensed consolidated balance sheet as of March 31, 2014. At the present time, we expect to deliver prototypes in the second quarter of 2014.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Consolidation: The financial statements include the accounts of the Company, our wholly-owned subsidiary Iso-Torque Corporation, and our majority-owned subsidiary, Ice Surface Development, Inc. (56% owned at March 31, 2014 and December 31, 2013). As of March 31, 2014, each of the subsidiaries is non-operational. We are intending to let Ice Surface Development, Inc. dissolve by proclamation. All material intercompany transactions and account balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates are used in valuing the useful lives of any intangible assets and the future realizable value of such assets. These estimates are subject to a high degree of judgment and potential change. Actual results could differ from those estimates.
Reclassification, Policy [Policy Text Block]	'
	Reclassifications: Certain reclassifications have been made to prior year balances to conform to the current year’s presentation.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents: Cash and cash equivalents may include time deposits, certificates of deposit, and highly liquid debt instruments with original maturities of three months or less. We maintain cash and cash equivalents at financial institutions which periodically may exceed federally insured amounts.
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable: We carry our accounts receivable at invoice amount less an allowance for doubtful accounts.  On a periodic basis, we evaluate our accounts receivable and establish an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions.  We do not accrue interest on past due invoices.  There was $0 allowance for doubtful accounts as of March 31, 2014 and December 31, 2013, as determined by management.
Inventory, Policy [Policy Text Block]	'
	Inventories: Inventories are stated at the lower of cost or market with cost determined under the first-in, first-out (FIFO) method. We record provisions for excess, obsolete or slow-moving inventory based on changes in customer demand, technology developments or other economic factors. There was a $24,000 and $26,000 provision for excess, obsolete or slow-moving inventory as of March 31, 2014 and December 31, 2013, respectively, as determined by management.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment: Property and equipment are stated at cost. Estimated useful lives are as follows:
	Office Equipment and Software (in years)		3-7
	Leasehold Improvements	Lesser of useful life or lease term
	Shop Equipment (in years)		7
	Transportation Equipment (in years)		5-7
	Depreciation and amortization are computed using the straight-line method. Betterments, renewals and extraordinary repairs that extend the life of the assets are capitalized. Other repairs and maintenance costs are expensed when incurred. When disposed, the cost and accumulated depreciation applicable to assets retired are removed from the accounts and the gain or loss on disposition is recognized in other income (expense). Depreciation and amortization expense for the three month periods ended March 31, 2014 and 2013 amounted to $43,000 and $32,000, respectively.
	Whenever events or circumstances indicate, our long-lived assets, including any intangible assets with finite useful lives, are tested for impairment by using the estimated future cash flows directly associated with, and that are expected to arise as a direct result of, the use of the assets. If the carrying amount exceeds the estimated undiscounted cash flows, an impairment may be indicated. The carrying amount is then compared to the estimated discounted cash flows, and if there is an excess, such amount is recorded as an impairment. During the three month periods ended March 31, 2014 and 2013, we recorded $0 in impairment charges.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments: As defined by U.S. GAAP, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. All assets and liabilities are required to be measured and reported on a fair value basis. A hierarchy for ranking the quality and reliability of the information is used to determine fair values. Assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).
	The FASB’s (Financial Accounting Standards Board) guidance for the disclosure about fair value of financial instruments requires disclosure of an estimate of the fair value of certain financial instruments. The fair value of financial instruments pursuant to FASB’s guidance for the disclosure about fair value of financial instruments approximated their carrying values at March 31, 2014 and December 31, 2013. The carrying amount of cash, accounts receivable, accounts payable, and accrued expenses approximates their fair value due to their short maturity. The carrying amount of notes payable approximates fair value because stated or implied interest rates approximate current interest rates that are available for debt with similar terms.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition: Our terms provide that customers are obligated to pay for products sold to them within a specified number of days from the date that title to the products is transferred to the customers. Our standard terms are typically net 30 days. We recognize revenue when transfer of title occurs, risk of ownership passes to a customer at the time of shipment or delivery depending on the terms of the agreement with a particular customer and collection is reasonably assured. The sale price of our products is substantially fixed and determinable at the date of the sale based upon purchase orders generated by a customer and accepted by us.
	We occasionally enter into prototype development contracts with customers. In such cases, revenue is recognized using either (a) the proportional effort method based on the relationship of costs incurred to date to the total estimated cost to complete a contract, or (b) where appropriate, the milestone method, if milestones are clearly identifiable and substantive.
	During the first quarter of 2013, we entered into a prototype development agreement with a Chinese automotive manufacturer to design, develop and manufacture an IsoTorque® differential for a specific vehicle application. Essentially, there is one performance milestone associated with the agreement, which is the delivery of our IsoTorque prototypes to the customer that they can test and evaluate. In total, the customer will pay us approximately $39,000 in two installments. We are deferring the recognition of revenue and related expenses pertaining to this development agreement until we achieve the delivery milestone. As of March 31, 2014, we have deferred approximately $20,000 in revenue and approximately $29,000 in expenses associated with this program.
In Process Research and Development, Policy [Policy Text Block]	'
	Research and Development and Patents: Research and development costs and patent expenses are charged to operations as incurred. Research and development includes personnel-related costs, materials and supplies, depreciation, consulting services, and amortization of acquired technology. Depreciation expense for the three month periods ended March 31, 2014 and 2013 that was charged to research and development was $24,000 and $10,000, respectively.
	Patent costs for the three month periods ended March 31, 2014 and 2013 amounted to $32,000 and $45,000, respectively, and are included in general and administrative expenses.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-based Compensation: FASB Accounting Standards Codification (“ASC”) 718-10 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the service period (generally the vesting period) in the consolidated financial statements based on their fair values on the grant date. Under the modified prospective method that we adopted, awards that were granted, modified, or settled on or after January 1, 2006 are measured and accounted for in accordance with ASC 718-10. Unvested equity-classified awards that were granted prior to January 1, 2006 will continue to be accounted for in accordance with ASC 718-10, except that the grant date fair value of all awards are recognized in the results of operations over the remaining vesting periods. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity in accordance with ASC 718-10.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets. We elected to adopt the alternative method of calculating the historical pool of windfall tax benefits as permitted by ASC 718-10-65 (previously known as: FASB Staff Position (FSP) No. SFAS 123(R)-c, “Transition Election Related to Accounting for the Tax Effects of Share-Based Payment Awards”). This is a simplified method to determine the pool of windfall tax benefits that is used in determining the tax effects of stock compensation in the results of operations and cash flow reporting for awards that were outstanding as of the adoption of ASC 718-10.
	FASB ASC 505-50, “Equity-Based Payments to Non-Employees,” requires all share-based payments to non-employees, including grants of stock options, to be recognized in the consolidated financial statements as compensation expense generally over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black-Scholes valuation model, we periodically reassess the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and we adjust the expense recognized in the consolidated financial statements accordingly.
	FASB ASC 718-20 requires that modifications of the terms or conditions of equity awards be treated as an exchange of the original award for a new award.  Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes: We account for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax bases of our assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.
	We account for uncertain tax positions using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax benefits that meet the more-likely-than-not recognition threshold should be measured as the largest amount of tax benefits, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement in the financial statements. It is our policy to recognize interest and penalties related to income tax matters as general and administrative expenses. As of March 31, 2014, there was $0 accrued interest or penalties related to uncertain tax positions. The tax years 2010 through 2013 remain open to examination by the federal and state tax jurisdictions to which we are subject. In addition, our 2009 tax year was examined by the Internal Revenue Service resulting in an inconclusive adjustment due to the expiration of the statute of limitations. Therefore, the Internal Revenue Service will conclude on any findings during a subsequent audit.
Earnings Per Share, Policy [Policy Text Block]	'
	Loss per Common Share: FASB’s ASC 260-10 (previously known as FASB Statement 128, “Earnings Per Share”) requires the presentation of basic earnings per share, which is based on weighted average common stock outstanding, and dilutive earnings per share, which gives effect to options, warrants and convertible securities in periods when they are dilutive. At March 31, 2014 and 2013, we excluded 53,721,662 and 29,108,682 potential common shares, respectively, relating to convertible preferred stock, options and warrants outstanding from the diluted net loss per common share calculation because their inclusion would be anti-dilutive. In addition, we excluded 625,000 warrants from the diluted net loss per common share calculation at March 31, 2014 and 2013 as the conditions for their vesting are not time-based.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements: In July 2013, FASB issued Accounting Standards Update (“ASU”) 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of this standard in the first quarter of 2014 did not have a material impact on the Company’s consolidated financial position and results of operations.

Note_B_Summary_of_Significant_1

Note B - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Office Equipment and Software (in years)		3-7
	Leasehold Improvements	Lesser of useful life or lease term
	Shop Equipment (in years)		7
	Transportation Equipment (in years)		5-7

Note_D_Inventories_Tables

Note D - Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		March 31,			December 31,
		2014			2013
	Raw Materials	$	24,000		$	26,000
	Finished Goods		13,000			0
	Total Inventories		37,000			26,000
	Reserve for Excess / Obsolete Inventory		(24,000	)		(26,000	)
	Inventories, Net	$	13,000		$	0

Note_E_Accrued_Liabilities_Tab

Note E - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Disclosure Text Block Supplement [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
		March 31,		December 31,
		2014		2013
	Accrued Compensation	$	28,000	$	53,000
	Accrued Payroll Taxes Payable		5,000		7,000
	Accrued Legal		12,000		8,000
	Other		24,000		2,000
		$	69,000	$	70,000

Note_F_Notes_Payable_Tables

Note F - Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
		March 31,2014		December 31,2013
	Copy Machine (1)	$	3,000	$	3,000
	Engineering Design Software (2)		8,000		14,000
	Test Equipment and Supplies (3)		7,000		27,000
	Automobile (4)		9,000		10,000
		$	27,000	$	54,000

Note_G_Stockholders_Equity_Tab

Note G - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			2014
	Expected Term (in years)			6.3
	Expected forfeiture rate			0	%
	Risk-free rate			1.9	%
	Volatility			134.3	%
	Dividend yield			0	%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Shares				Weighted				Weighted				Aggregate
							Average				Average				Intrinsic
							Exercise				Remaining				Value
							Price				Contractual
											Term (in years)
	Outstanding at January 1, 2014			8,470,336	(A)		$	0.69
	Granted			500				0.34
	Exercised			0				0
	Canceled or expired			0				0
	Outstanding at March 31, 2014			8,470,836	(A)		$	0.69				6.6			$	315,000
	Exercisable at March 31, 2014			5,346,832			$	0.81				6.5			$	180,000
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Exercise				Expiration				Number of Warrants				Number of
		Price								Outstanding				Warrants
														Exercisable
		Not yet determinable				Not yet determinable					125,000	(a)			0
		$	0.75			None					500,000	(b)			0
		$	0.01				2015-2016				54,500	(c)			54,500
		$	0.01			None					3,000	(d)			3,000
		$	5			None					55,000	(e)			55,000
		$	5				2016				66,668	(e)			66,668
		$	0.01			None					60,000	(f)			60,000
		$	0.01				2016				3,750	(g)			3,750
		$	1			None					20,500	(h)			20,500
		$	0.44				2020				400,000	(i)			400,000
		$	3.75				2016				200,000	(j)			200,000
		$	5				2016				30,000	(k)			30,000
		$	5				2017				50,000	(l)			50,000
		$	5				2017				100,000	(m)			100,000
		$	2.5				2020				100,000	(n)			100,000
		Not yet determinable				2021					1,625,000	0			1,625,000
											3,393,418				2,768,418
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			Shares				Weighted				Weighted				Aggregate
							Average				Average				Intrinsic
							Exercise				Remaining				Value
							Price				Contractual
											Term (in years)
	Outstanding at January 1, 2014			3,393,418			$	2.06	(A)
	Granted			0				0
	Exercised			0				0
	Canceled or expired			0				0
	Outstanding at March 31, 2014			3,393,418			$	2.06	(A)			6.3	(B)		$	162,000
	Exercisable at March 31, 2014			2,768,418			$	2.63				6.3	(C)		$	162,000

Note_B_Summary_of_Significant_2

Note B - Summary of Significant Accounting Policies (Details) (USD $)

3 Months Ended

210 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

BAIC [Member]

BAIC [Member]

BAIC [Member]

Warrant [Member]

Warrant [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Subsidiaries [Member]

Subsidiaries [Member]

Minimum [Member]

Maximum [Member]

Patents [Member]

Patents [Member]

Note B - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Method Investment, Ownership Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

56.00%

56.00%

'

'

Allowance for Doubtful Accounts Receivable, Current

'

'

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory Valuation Reserves

24,000

'

24,000

26,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation, Depletion and Amortization

43,000

32,000

2,882,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Asset Impairment Charges

0

0

1,071,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Value of Development Project

'

'

'

'

'

39,000

39,000

'

'

'

'

'

'

'

'

'

'

Deferred Revenue

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid Expense and Other Assets, Current

47,000

'

47,000

31,000

29,000

'

'

'

'

'

'

'

'

'

'

'

'

Depreciation

'

'

'

'

'

'

'

'

'

24,000

10,000

'

'

'

'

'

'

Research and Development Expense

376,000

258,000

19,831,000

'

'

'

'

'

'

'

'

32,000

45,000

'

'

'

'

Employee Service Share-based Compensation, Tax Benefit from Compensation Expense

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued

$0

'

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Open Tax Year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2010

'2013

Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)

53,721,662

29,108,682

'

'

'

'

'

625,000

625,000

'

'

'

'

'

'

'

'

Note_B_Summary_of_Significant_3

Note B - Summary of Significant Accounting Policies (Details) - Property and Equipment, Estimated Useful Lives	3 Months Ended
	Mar. 31, 2014
Machinery and Equipment [Member]	'
Property, Plant and Equipment [Line Items]	'
Useful lives	'7 years
Transportation Equipment [Member] | Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Useful lives	'5 years
Transportation Equipment [Member] | Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Useful lives	'7 years

Note_C_Related_Party_Transacti1

Note C - Related Party Transactions (Details) (USD $)

Dec. 04, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2011

Dec. 13, 2010

31-May-12

Apr. 30, 2012

Mar. 31, 2014

Mar. 31, 2013

Apr. 30, 2014

Mar. 31, 2014

Mar. 31, 2013

Dec. 04, 2013

Jan. 31, 2013

Dec. 31, 2012

Additional Hours [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

KBE Inc [Member]

KBE Inc [Member]

KBE Inc [Member]

KBE Inc [Member]

KBE Inc [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

Note C - Related Party Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Pary Transaction, Expenses from Transactions with Related Party, Rate (in Dollars per Hour)

125

'

'

'

200

'

'

'

'

'

'

'

2,000

3,840

3,840

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

'

'

'

'

$10,000

'

'

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Revenue Benchmark

'

'

'

1,000,000

1,000,000

'

'

'

'

'

'

'

'

'

'

Professional Fees

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

Due to Related Parties

'

3,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Expenses from Transactions with Related Party

'

'

'

'

'

'

162,500

'

'

'

7,000

12,000

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

6,800

'

'

'

'

'

Debt Instrument, Payment Terms

'

'

'

'

'

'

'

'

'

'5%

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

'

'

'

154,000

'

'

'

'

'

Due from Related Parties

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

Interest Expense, Related Party

'

'

'

'

'

'

'

0

1,000

'

'

'

'

'

'

Supplies Expense

'

'

'

'

'

$5,700

'

'

'

'

'

'

'

'

'

Related Pary Transaction, Expenses from Transactions with Related Party, Rate (in Dollars per Month)

125

'

'

'

200

'

'

'

'

'

'

'

2,000

3,840

3,840

Note_D_Inventories_Details_Inv

Note D - Inventories (Details) - Inventories (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Raw Materials	$24,000	$26,000
Finished Goods	13,000	0
Total Inventories	37,000	26,000
Reserve for Excess / Obsolete Inventory	-24,000	-26,000
Inventories, Net	$13,000	$0

Note_E_Accrued_Liabilities_Det

Note E - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]	'	'
Accrued Compensation	$28,000	$53,000
Accrued Payroll Taxes Payable	5,000	7,000
Accrued Legal	12,000	8,000
Other	24,000	2,000
	$69,000	$70,000

Note_F_Notes_Payable_Details

Note F - Notes Payable (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Apr. 30, 2012

Nov. 30, 2010

Mar. 31, 2014

Dec. 31, 2013

Aug. 31, 2011

Mar. 31, 2014

Dec. 31, 2013

Aug. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Nov. 30, 2010

Office Equipment [Member]

Office Equipment [Member]

Office Equipment [Member]

Office Equipment [Member]

Software and Software Development Costs [Member]

Software and Software Development Costs [Member]

Software and Software Development Costs [Member]

Vehicles [Member]

Vehicles [Member]

Vehicles [Member]

Capital Lease Obligations [Member]

Note F - Notes Payable (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Capital Lease Term

'

'

'

'5

'

'

'

'

'

'

'

'

'

Capital Leased Assets, Gross

'

'

'

$8,900

'

'

'

'

'

'

'

'

'

Capital Lease Monthly Payment

'

'

'

170

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate During Period

'

'

'

'

'

'

9.60%

'

'

'

'

'

5.30%

Capital Lease Obligations

'

'

'

'

3,000

3,000

'

'

'

'

'

'

'

Capital Lease Obligations, Noncurrent

'

'

'

'

'

2,000

'

'

'

'

'

'

'

Notes Payable, Noncurrent

4,000

6,000

'

'

1,000

'

'

'

'

'

3,000

4,000

'

Capitalized Computer Software, Gross

'

'

'

'

'

'

64,800

'

'

'

'

'

'

Long Term Loan Monthly Payment

'

'

'

'

'

'

2,100

'

'

'

'

'

'

Notes Payable, Current

23,000

48,000

'

'

7,000

27,000

'

8,000

14,000

'

'

'

'

Notes Payable

27,000

54,000

162,500

'

'

'

'

'

'

16,600

9,000

10,000

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

5.00%

'

'

'

'

'

'

10.00%

'

'

'

Debt Instrument, Face Amount

'

'

154,000

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment

'

'

$6,800

'

'

'

'

'

'

$540

'

'

'

Note_F_Notes_Payable_Details_N

Note F - Notes Payable (Details) - Notes Payable (USD $)	Mar. 31, 2014		Dec. 31, 2013
Note F - Notes Payable (Details) - Notes Payable [Line Items]	'		'
Long-Term Notes Payable	$27,000		$54,000
Copy Machine [Member]	'		'
Note F - Notes Payable (Details) - Notes Payable [Line Items]	'		'
Long-Term Notes Payable	3,000	[1]	3,000	[1]
Engineering Design Software [Member]	'		'
Note F - Notes Payable (Details) - Notes Payable [Line Items]	'		'
Long-Term Notes Payable	8,000	[2]	14,000	[2]
Test Equipment and Supplies [Member]	'		'
Note F - Notes Payable (Details) - Notes Payable [Line Items]	'		'
Long-Term Notes Payable	7,000	[3]	27,000	[3]
Automobile [Member]	'		'
Note F - Notes Payable (Details) - Notes Payable [Line Items]	'		'
Long-Term Notes Payable	$9,000	[4]	$10,000	[4]
[1]	In November 2010, we entered into a capital lease for a copy machine over a 5 year term, with a fair market value buyout. The capitalized value of the lease was approximately $8,900, and the monthly payment is approximately $170 with an implicit interest rate of approximately 5.3%. At December 31, 2013, the outstanding balance on this note was approximately $3,000, of which $2,000 wasclassified as a non-current liability. At March 31, 2014, the outstanding balance on this note was approximately $3,000, of which $1,000was classified as a non-current liability.
[2]	In August 2011, we financed the purchase of engineering design software, along with a one-year maintenance agreement, through a three year loan maturing in August 2014, and collateralized by the software. The total cost of the software and the maintenance agreement was approximately $64,800. The monthly payments are approximately $2,100 per month with an implicit interest rate of approximately 9.6%. At December 31, 2013, the outstanding balance on this note was approximately $14,000, which was classified as a current liability.At March 31, 2014, the outstanding balance on this note was approximately $8,000, which was classified as a current liability.
[3]	In April 2012, we financed the purchase of various test equipment, office furniture, and supplies from KBE+, Inc. (of which our chief technology officer is an officer) through a 24 month promissory note for a total amount to be paid of $162,500. Based on an imputed interest rate of approximately 5%, the initial principal of the note was approximately $154,000. The monthly payments are approximately $6,800 per month. At December 31, 2013, the outstanding balance on this related party note was approximately $27,000, which wasclassified as a current liability. At March 31, 2014, the outstanding balance on this related party note was approximately $7,000, which was classified as a current liability.
[4]	In August 2012, we purchased an automobile for $16,600, a vehicle that we had previously been leasing. We financed this purchase with a 36- month promissory note. The interest rate on the loan is approximately 10%, and the payments are approximately $540 per month. At December 31, 2013, the outstanding balance on this note was approximately $10,000, of which $4,000 was classified as a non-current liability. At March 31, 2014, the outstanding balance on this note was approximately $9,000, of which $3,000 was classified as a non-current liability.

Note_G_Stockholders_Equity_Det

Note G - Stockholders' Equity (Details) (USD $)

3 Months Ended

210 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

90 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

111 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

144 Months Ended

145 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

115 Months Ended

31 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

147 Months Ended

195 Months Ended

1 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 28, 2014

Dec. 31, 2013

Aug. 30, 2000

Dec. 31, 2011

Sep. 23, 2011

Mar. 31, 2014

Feb. 28, 2014

Aug. 31, 2013

Nov. 30, 2013

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2011

Mar. 31, 2014

Apr. 15, 2002

Apr. 15, 2002

Apr. 15, 2002

Mar. 31, 2014

Dec. 31, 2002

Dec. 31, 2003

Apr. 15, 2002

Apr. 15, 2002

Oct. 13, 2006

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2010

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2006

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2008

Mar. 31, 2014

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2006

Dec. 31, 2005

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2006

Oct. 15, 2006

Mar. 31, 2014

Dec. 31, 2010

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2007

Mar. 31, 2014

Dec. 31, 2007

Feb. 17, 2010

Mar. 31, 2014

Mar. 31, 2010

Sep. 23, 2011

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2002

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2006

Dec. 31, 2005

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2004

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2006

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2011

Sep. 30, 2011

Sep. 23, 2011

Mar. 31, 2014

Sep. 30, 2011

Mar. 28, 2014

Mar. 31, 2014

Mar. 28, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 1997

Jan. 31, 2011

Mar. 31, 2014

Mar. 31, 2013

Sep. 23, 2011

Mar. 31, 2014

Mar. 31, 2014

Amended [Member]

Convertible [Member]

Stock Option Plan 1998 [Member]

Incentive Stock Options [Member]

Incentive Stock Options [Member]

Non-Qualified Stock Options [Member]

Non-Plan Options [Member]

Non-Plan Options [Member]

Non-Employee Mark to-Market Adjustments [Member]

Replacement Options [Member]

Replacement Options [Member]

Replacement Options [Member]

Replacement Options [Member]

Replacement Options [Member]

Replacement Options [Member]

Warrant B1 [Member]

Warrant B2 [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant C [Member]

Warrant C [Member]

Warrant C [Member]

Warrant D [Member]

Warrant D [Member]

Warrant D [Member]

Warrant E1 [Member]

Warrant E1 [Member]

Warrant E1 [Member]

Warrant E2 [Member]

Warrant E2 [Member]

Warrant E2 [Member]

Warrant E2 [Member]

Warrant E2 [Member]

Warrant F [Member]

Warrant F [Member]

Warrant G [Member]

Warrant G [Member]

Warrant G [Member]

Warrant G [Member]

Warrant H [Member]

Warrant H [Member]

Warrant I [Member]

Warrant I [Member]

Warrant I [Member]

Warrant I [Member]

Warrant J [Member]

Warrant J [Member]

Warrant K [Member]

Warrant K [Member]

Warrant L [Member]

Warrant L [Member]

Warrant M [Member]

Warrant M [Member]

Warrant N [Member]

Warrant N [Member]

Warrant N [Member]

Warrant O [Member]

Warrant O [Member]

Warrants, No Determined Exercise Price [Member]

Warrants, No Determined Exercise Price [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Preferred Class A [Member]

Convertible Preferred Stock [Member]

Preferred Class B [Member]

Preferred Class B [Member]

Preferred Class B [Member]

Preferred Class B [Member]

Preferred Class B [Member]

Preferred Class B [Member]

Preferred Class C [Member]

Preferred Class C [Member]

Preferred Class C [Member]

Preferred Class C [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C-2 Preferred Stock [Member]

Series C-2 Preferred Stock [Member]

Series C-3 Preferred Stock [Member]

Stock Option Plan 1998 [Member]

Stock Option Plan 1998 [Member]

Stock Option Plan 1998 [Member]

Stock Option Plan 1998 [Member]

Stock Option Plan 1998 [Member]

Stock Option Plan 2011 [Member]

Stock Option Plan 2011 [Member]

Stock Option Plan 2011 [Member]

Estimate of Fair Value Measurement [Member]

Minimum [Member]

Maximum [Member]

Warrant E2 [Member]

Series C Preferred Stock [Member]

Stock Option Plan 2011 [Member]

Stock Option Plan 2011 [Member]

Stock Option Plan 2011 [Member]

Previous Issuance [Member]

Previous Issuance [Member]

Warrant B [Member]

Warrant B [Member]

Minimum [Member]

Maximum [Member]

Note G - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

100,000,000

'

100,000,000

'

100,000,000

100,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

3,300,000

'

3,300,000

'

'

3,300,000

3,300,000

'

300,000

300,000

'

300,000

'

300,000

16,250,000

16,250,000

'

16,250,000

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

$0.01

'

$0.01

'

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividends Per Share, Declared (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

0

162,000

62,500

'

765,512

'

'

0

'

0

20,000

97,500

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock and Preference Stock (in Dollars)

$4,954,000

$0

$14,885,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,500,000

'

'

'

'

'

'

'

'

'

'

$3,062,000

'

'

'

'

'

'

$487,500

'

'

'

'

$6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

189,750

'

'

0

'

'

'

30,000

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

1

1

'

'

1

'

'

'

1

'

'

'

'

'

'

1

1

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Dividends, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

11,339

'

'

'

0

0

'

'

35,431

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends, Preferred Stock (in Dollars)

66,000

66,000

2,544,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

242,000

'

'

'

'

'

'

'

51,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Dividends, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,924

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

587,101

'

587,101

'

'

587,101

587,101

'

'

67,500

'

67,500

'

67,500

16,250,000

16,250,000

'

'

'

16,250,000

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Units, Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

575,762

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends Payable (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,076,000

'

294,000

'

'

'

294,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividends (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

58,000

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference, Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,076,000

'

2,019,000

'

'

2,076,000

2,076,000

'

'

294,000

'

285,000

'

294,000

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

'

'

'

'

$4

$4

'

'

$5

'

'

'

$5

'

'

'

'

'

$0.40

'

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued

'

'

'

'

'

'

'

16,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

587,101

'

587,101

'

'

587,101

587,101

'

'

67,500

'

67,500

'

67,500

16,250,000

16,250,000

'

'

16,250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

'

110,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

[1]

'

'

'

'

'

54,500

[2]

54,500

[2]

3,000

[3]

'

'

55,000

[4]

'

'

66,668

[4]

'

'

'

'

60,000

[5]

'

3,750

[6]

'

'

3,750

[6]

20,500

[7]

'

'

400,000

[8]

'

'

200,000

[9]

'

30,000

[10]

'

50,000

[11]

'

100,000

[12]

'

'

100,000

[13]

'

'

1,625,000

[14]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Stock Issuance Costs (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

106,000

'

'

46,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Preferred Stock, Net of Issuance Cost (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,394,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'10 years

'

'

'10 years

'

'10 years

'

'10 years

'

'10 years

'

'10 years

'10 years

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'

'

'

'

'10 years

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.01

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,750,000

1,750,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

812,000

'

'

'

'

'

'

'

'

'

'

'

'

'

812,000

'

'

Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,582,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Value, Outstanding (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Private Placement (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,954,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

$0.01

'

$0.01

$0.01

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Reserved to be Issued, Value (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,250,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

3,000,000

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

10.00%

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

110.00%

'

'

'

'

'

110.00%

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'3 years

'

'

'4 years

'4 years

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

0

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

0

0

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,823,895

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

1,723,895

'

'

0

0

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

8,470,836

[15]

'

8,470,836

[15]

'

8,470,336

[15]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

100,000

100,000

'

'

1,307,500

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

4,575,836

'

'

'

'

'

'

'

135,004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

100,000

100,000

'

'

670,996

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

497,000

'

497,000

'

'

'

'

'

'

'

'

'

'

'

16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

0

0

'

'

15,000

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

500

0

'

'

'

'

'

'

'

500

25,000

100,000

'

'

'

'

'

'

'

405,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

500

0

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

0

0

2,463,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

109,000

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$0.34

'

'

'

'

'

'

'

'

$0.34

$0.45

$0.36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

'

'

'

'

'

'

'

'

'

25.00%

25.00%

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,250

125,250

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,692,500

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

7,063,336

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

'

'

'

'

'

'

337,500

337,500

'

'

'

134,998

134,998

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised

0

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

250,000

250,000

'

'

'

'

69,000

'

6,000

3,500

'

'

'

'

'

'

'

'

'

'

'

'

'

194,599

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

(in Dollars)

13,000

229,000

22,429,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

'3 years 328 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

$0.34

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)

688,000

680,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,666

36,666

98,332

98,332

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.34

$5

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

123,500

'

'

'

'

12,500

'

100,000

95,000

'

'

'

95,000

195,000

'

60,000

'

135,849

62,500

'

'

20,500

400,000

'

'

400,000

'

200,000

'

30,000

'

50,000

'

100,000

100,000

'

'

1,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Investment Warrants, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.75

$0.30

$0.50

$0.30

$0.75

$0.01

$0.01

'

$0.01

'

$0.01

$5

$5

$5

$5

'

'

'

$5

$0.01

'

$0.01

$0.01

$0.01

'

$1

$1

$0.44

$0.44

'

$3.27

$3.75

$3.75

$5

$5

$5

$5

$5

$5

$2.50

$2.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

5,346,832

'

5,346,832

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

250,000

'

0

'

'

'

'

'

54,500

54,500

3,000

'

'

55,000

'

'

66,668

'

'

'

'

60,000

'

3,750

'

'

3,750

20,500

'

'

400,000

'

'

200,000

'

30,000

'

50,000

'

100,000

'

'

100,000

'

'

1,625,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in Dollars per share)

$0.81

'

$0.81

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

125,000

'

'

'

'

690

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,258

'

2,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Unissued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

General and Administrative Expense (in Dollars)

328,000

508,000

51,278,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

249,000

'

'

'

'

'

'

'

'

'

'

68,000

'

'

'

'

'

'

249,000

'

401,000

'

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in Dollars per share)

$0

'

'

'

'

'

$1.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized Share-based Compensation Cost Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,666

36,666

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

136.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Without Expiration Date Outstanding

763,500

'

763,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Without Expiration Date Exercisable

138,500

'

138,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

On April 15, 2002, we issued 1,000,000 warrants at prices ranging from $0.30 to $0.75 to our then chairman of the board of directors and chief executive officer. Of the total warrants, 250,000 were exercisable at $0.30, and 250,000 were exercisable at $0.50 on the date the then board elected the executive to the board and named him chief executive officer. During the year ended December 31, 2002, 250,000 warrants were exercised for $0.30 per share, resulting in proceeds of $75,000. During the year ended December 31, 2003, 250,000 warrants were exercised for $0.50 per share, resulting in proceeds of $125,000. The remaining 500,000 warrants are exercisable upon the occurrence of a significant transaction, which includes execution by us of a binding agreement for the sale, transfer, license or assignment for value of any and/or all of our automotive technology, at $0.75 per share. We will record a charge representing the fair value of the warrants when the warrants become exercisable.

[2]

We issued an aggregate 123,500 warrants at an exercise price of $0.01 with a ten year term to our nonmanagement directors for services rendered to the board under our Nonmanagement Directors Plan prior to its amendment on October 13, 2006. There are 0 further warrants issuable under the Plan as modified by the board of directors on October 13, 2006. An aggregate 69,000 warrants have been exercised for proceeds of $690.

[3]

In 2005, we issued 12,500 warrants to consultants, immediately exercisable at $0.01 per common share. During 2005 and 2006, 3,500 of these warrants were exercised. During 2010, an additional 6,000 of these warrants were exercised. The 3,000 remaining outstanding warrants have no expiration date.

[4]

In 2005, we issued 95,000 warrants to two engineering and administrative consultants, exercisable immediately at $5.00 per common share. During 2006, we issued an additional 100,000 warrants to these same consultants exercisable over a ten year term at $5.00 per common share, but only exercisable if there is a commercializing event as determined by the board of directors. During 2008, these warrants were cancelled and new warrants were issued to the same consultants for an aggregate 195,000 shares exercisable until 2016 at $5.00 per common share and conditioned upon the happening of a commercializing event as determined by the board. We recorded a charge of $249,000 in 2008 to general and administrative expense. In 2010, 95,000 of the total number of 195,000 warrants issued to these consultants were modified to eliminate both the term and the commercializing event condition for exercise. The charge related to the 2010 modification was insignificant. In December 2011, 110,000 of these outstanding warrants were amended so that they will be cancelled in conjunction with the vesting of stock options that were issued to replace such warrants, with each option having an exercise price of $1.14 per share, and proportionate vesting on each of the succeeding anniversary dates over a three year period. The approximately $16,000 expense related to the issuance of the stock options to replace the warrants is being amortized over the vesting period of the stock options. In the fourth quarter of 2012, 36,666 of these warrants were cancelled as the corresponding number of options vested. In the fourth quarter of 2013, another 36,666 of these warrants were cancelled as the corresponding number of options vested.

[5]

During 2005, we issued 60,000 warrants to an engineering consultant exercisable immediately at $5.00 per common share and with no expiration date.

[6]

During 2005, we issued 62,500 warrants to investors in connection with their purchase of 62,500 Class A Preferred, immediately exercisable at $0.01 per common share and with a ten year term. During 2006, we issued 135,849 warrants to investors along with their purchase of 162,000 Class A Preferred and 20,000 Class B Preferred, all immediately exercisable at $0.01 per common share and with a ten year term. Through March 31, 2014, an aggregate of 194,599 of these warrants have been exercised for proceeds of approximately $1,258. There were 0 warrants exercised during the three month period ended March 31, 2014.

[7]

During 2006, one investor purchased 20,500 warrants with no expiration date and an exercise price of $1.00 per common share, for a purchase price of $2,000.

[8]

During 2006, we issued 400,000 warrants immediately exercisable for ten years at an exercise price of $3.27 per common share to a business consultant. Effective October 15, 2010, these warrants were modified and reissued upon the mutual agreement of the parties. Effective October 15, 2010, we issued 400,000 warrants immediately exercisable at $0.44 per common share for a period of ten years from the modification date. As a result of the modification, we recorded a charge of $68,000 to general and administrative expenses in the fourth quarter of 2010. During the three month period ended March 31, 2014, 0 warrants were exercised.

[9]

During 2006, we issued 200,000 warrants immediately exercisable for ten years at an exercise price of $3.75 per common share to a former governmental affairs consultant.

[10]

In 2006, we issued 30,000 warrants to consultants exercisable immediately for a ten year term at $5.00 per common share.

[11]

During 2007, we issued 50,000 warrants exercisable for ten years at $5.00 per common share upon the happening of a commercializing event. The warrants were issued to a consultant who assisted us to potentially place our products in various state school bus programs. We recorded a charge of $249,000 to general and administrative expenses.

[12]

During 2007, we issued 100,000 warrants immediately exercisable for ten years at an exercise price of $5.00 per common share to two engineering consultants in connection with our engagement to furnish constant velocity joints to a military contractor. We recorded a charge of $401,000 to general and administrative expenses.

[13]

On February 17, 2010, we issued 100,000 common stock warrants exercisable for ten years at an exercise price of $2.50 per common share to an adviser. We recorded a charge of $45,000 to general and administrative expenses in the first quarter of 2010.

[14]

On September 23, 2011, we issued 1,625,000 common stock warrants in connection with the sale and issuance of a total of 16,250,000 shares of Series C Voting Convertible Preferred Stock in a private placement transaction, generating gross proceeds of $6,500,000. The warrants have a ten (10) year term and are immediately exercisable for 1,625,000 shares of common stock. The warrants are exercisable, at the holder's election, for shares of our common stock in either a cash or cashless exercise. The warrants have an exercise price equal to the greater of (i) $0.01 or (ii) eighty percent (80%) of the volume weighted average sale price per share of our common stock during the ten (10) consecutive trading days immediately preceding the notice of exercise. The number of warrants and exercise price are subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock. (See Note G[1](c).)

[15]

Figures include the impact of 405,000 options that were granted in 2011 to replace options / warrants previously granted to certain engineering personnel. The previously issued options / warrants will expire as the newer options vest on a one-to-one basis. During the fourth quarter of 2012, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011. Again during 2013, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011 options. As of March 31, 2014, there are 135,004 of the 2011 options remaining to vest.

Note_G_Stockholders_Equity_Det1

Note G - Stockholders' Equity (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions	3 Months Ended
	Mar. 31, 2014
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]	'
Expected Term (in years)	'6 years 109 days
Expected forfeiture rate	0.00%
Risk-free rate	1.90%
Volatility	134.30%
Dividend yield	0.00%

Note_G_Stockholders_Equity_Det2

Note G - Stockholders' Equity (Details) - Share-based Compensation, Stock Options, Activity (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013	Dec. 31, 2013
Share-based Compensation, Stock Options, Activity [Abstract]	'		'	'
Shares Outstanding	8,470,836	[1]	'	8,470,336	[1]
Weighted Average Exercise Price	$0.69		'	$0.69
Weighted Average Remaining Contractual Term	'6 years 219 days		'	'
Aggregate Intrinsic Value	$315,000		'	'
Exercisable at March 31, 2014	5,346,832		'	'
Exercisable at March 31, 2014	$0.81		'	'
Exercisable at March 31, 2014	'6 years 6 months		'	'
Exercisable at March 31, 2014	$180,000		'	'
Granted	500		0	'
Granted	$0.34		'	'
Exercised	0		'	'
Exercised	$0		'	'
Canceled or expired	0		'	'
Canceled or expired	$0		'	'
[1]	Figures include the impact of 405,000 options that were granted in 2011 to replace options / warrants previously granted to certain engineering personnel. The previously issued options / warrants will expire as the newer options vest on a one-to-one basis. During the fourth quarter of 2012, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011. Again during 2013, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011 options. As of March 31, 2014, there are 135,004 of the 2011 options remaining to vest.

Note_G_Stockholders_Equity_Det3

Note G - Stockholders' Equity (Details) - Stockholders' Equity Note, Warrants (USD $)

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2002

Dec. 31, 2003

Apr. 15, 2002

Apr. 15, 2002

Oct. 13, 2006

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2006

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2008

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2006

Dec. 31, 2005

Mar. 31, 2014

Dec. 31, 2006

Oct. 15, 2006

Mar. 31, 2014

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2006

Mar. 31, 2014

Dec. 31, 2007

Mar. 31, 2014

Dec. 31, 2007

Feb. 17, 2010

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Warrant A [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant B [Member]

Warrant C [Member]

Warrant C [Member]

Warrant C [Member]

Warrant C [Member]

Warrant D [Member]

Warrant D [Member]

Warrant E1 [Member]

Warrant E1 [Member]

Warrant E1 [Member]

Warrant E2 [Member]

Warrant E2 [Member]

Warrant F [Member]

Warrant G [Member]

Warrant G [Member]

Warrant G [Member]

Warrant H [Member]

Warrant H [Member]

Warrant I [Member]

Warrant I [Member]

Warrant I [Member]

Warrant J [Member]

Warrant J [Member]

Warrant K [Member]

Warrant K [Member]

Warrant L [Member]

Warrant L [Member]

Warrant M [Member]

Warrant M [Member]

Warrant N [Member]

Warrant N [Member]

Warrant O [Member]

Warrant [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Class of Warrant or Right [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price (in Dollars per share)

'

'

$0.75

$0.30

$0.50

$0.30

$0.75

$0.01

$0.01

'

'

$0.01

$0.01

$5

$5

$5

$5

$5

$0.01

$0.01

$0.01

$0.01

$1

$1

$0.44

$0.44

$3.27

$3.75

$3.75

$5

$5

$5

$5

$5

$5

$2.50

$2.50

'

'

Expiration

'

'

'

'

'

'

'

'

'

31-Dec-15

31-Dec-16

'

'

'

'

'

31-Dec-16

'

'

31-Dec-16

'

'

'

'

'

31-Dec-20

'

31-Dec-16

'

31-Dec-16

'

31-Dec-17

'

31-Dec-17

'

'

31-Dec-20

31-Dec-21

'

Number of Warrants Outstanding

'

125,000

[1]

500,000

[2]

'

'

'

'

'

54,500

[3]

'

'

3,000

[4]

'

55,000

[5]

'

'

66,668

[5]

'

60,000

[6]

3,750

[7]

'

'

20,500

[8]

'

'

400,000

[9]

'

200,000

[10]

'

30,000

[11]

'

50,000

[12]

'

100,000

[13]

'

'

100,000

[14]

1,625,000

[15]

3,393,418

Number of Warrants Exercisable

5,346,832

0

0

'

'

'

'

'

54,500

'

'

3,000

'

55,000

'

'

66,668

'

60,000

3,750

'

'

20,500

'

'

400,000

'

200,000

'

30,000

'

50,000

'

100,000

'

'

100,000

1,625,000

2,768,418

[1]

Exercisable only if we have an IPO and exercisable at the IPO price five years from IPO. Through March 31, 2014, we have not conducted an IPO.

[2]

On April 15, 2002, we issued 1,000,000 warrants at prices ranging from $0.30 to $0.75 to our then chairman of the board of directors and chief executive officer. Of the total warrants, 250,000 were exercisable at $0.30, and 250,000 were exercisable at $0.50 on the date the then board elected the executive to the board and named him chief executive officer. During the year ended December 31, 2002, 250,000 warrants were exercised for $0.30 per share, resulting in proceeds of $75,000. During the year ended December 31, 2003, 250,000 warrants were exercised for $0.50 per share, resulting in proceeds of $125,000. The remaining 500,000 warrants are exercisable upon the occurrence of a significant transaction, which includes execution by us of a binding agreement for the sale, transfer, license or assignment for value of any and/or all of our automotive technology, at $0.75 per share. We will record a charge representing the fair value of the warrants when the warrants become exercisable.

[3]

We issued an aggregate 123,500 warrants at an exercise price of $0.01 with a ten year term to our nonmanagement directors for services rendered to the board under our Nonmanagement Directors Plan prior to its amendment on October 13, 2006. There are 0 further warrants issuable under the Plan as modified by the board of directors on October 13, 2006. An aggregate 69,000 warrants have been exercised for proceeds of $690.

[4]

In 2005, we issued 12,500 warrants to consultants, immediately exercisable at $0.01 per common share. During 2005 and 2006, 3,500 of these warrants were exercised. During 2010, an additional 6,000 of these warrants were exercised. The 3,000 remaining outstanding warrants have no expiration date.

[5]

In 2005, we issued 95,000 warrants to two engineering and administrative consultants, exercisable immediately at $5.00 per common share. During 2006, we issued an additional 100,000 warrants to these same consultants exercisable over a ten year term at $5.00 per common share, but only exercisable if there is a commercializing event as determined by the board of directors. During 2008, these warrants were cancelled and new warrants were issued to the same consultants for an aggregate 195,000 shares exercisable until 2016 at $5.00 per common share and conditioned upon the happening of a commercializing event as determined by the board. We recorded a charge of $249,000 in 2008 to general and administrative expense. In 2010, 95,000 of the total number of 195,000 warrants issued to these consultants were modified to eliminate both the term and the commercializing event condition for exercise. The charge related to the 2010 modification was insignificant. In December 2011, 110,000 of these outstanding warrants were amended so that they will be cancelled in conjunction with the vesting of stock options that were issued to replace such warrants, with each option having an exercise price of $1.14 per share, and proportionate vesting on each of the succeeding anniversary dates over a three year period. The approximately $16,000 expense related to the issuance of the stock options to replace the warrants is being amortized over the vesting period of the stock options. In the fourth quarter of 2012, 36,666 of these warrants were cancelled as the corresponding number of options vested. In the fourth quarter of 2013, another 36,666 of these warrants were cancelled as the corresponding number of options vested.

[6]

During 2005, we issued 60,000 warrants to an engineering consultant exercisable immediately at $5.00 per common share and with no expiration date.

[7]

During 2005, we issued 62,500 warrants to investors in connection with their purchase of 62,500 Class A Preferred, immediately exercisable at $0.01 per common share and with a ten year term. During 2006, we issued 135,849 warrants to investors along with their purchase of 162,000 Class A Preferred and 20,000 Class B Preferred, all immediately exercisable at $0.01 per common share and with a ten year term. Through March 31, 2014, an aggregate of 194,599 of these warrants have been exercised for proceeds of approximately $1,258. There were 0 warrants exercised during the three month period ended March 31, 2014.

[8]

During 2006, one investor purchased 20,500 warrants with no expiration date and an exercise price of $1.00 per common share, for a purchase price of $2,000.

[9]

During 2006, we issued 400,000 warrants immediately exercisable for ten years at an exercise price of $3.27 per common share to a business consultant. Effective October 15, 2010, these warrants were modified and reissued upon the mutual agreement of the parties. Effective October 15, 2010, we issued 400,000 warrants immediately exercisable at $0.44 per common share for a period of ten years from the modification date. As a result of the modification, we recorded a charge of $68,000 to general and administrative expenses in the fourth quarter of 2010. During the three month period ended March 31, 2014, 0 warrants were exercised.

[10]

During 2006, we issued 200,000 warrants immediately exercisable for ten years at an exercise price of $3.75 per common share to a former governmental affairs consultant.

[11]

In 2006, we issued 30,000 warrants to consultants exercisable immediately for a ten year term at $5.00 per common share.

[12]

During 2007, we issued 50,000 warrants exercisable for ten years at $5.00 per common share upon the happening of a commercializing event. The warrants were issued to a consultant who assisted us to potentially place our products in various state school bus programs. We recorded a charge of $249,000 to general and administrative expenses.

[13]

During 2007, we issued 100,000 warrants immediately exercisable for ten years at an exercise price of $5.00 per common share to two engineering consultants in connection with our engagement to furnish constant velocity joints to a military contractor. We recorded a charge of $401,000 to general and administrative expenses.

[14]

On February 17, 2010, we issued 100,000 common stock warrants exercisable for ten years at an exercise price of $2.50 per common share to an adviser. We recorded a charge of $45,000 to general and administrative expenses in the first quarter of 2010.

[15]

On September 23, 2011, we issued 1,625,000 common stock warrants in connection with the sale and issuance of a total of 16,250,000 shares of Series C Voting Convertible Preferred Stock in a private placement transaction, generating gross proceeds of $6,500,000. The warrants have a ten (10) year term and are immediately exercisable for 1,625,000 shares of common stock. The warrants are exercisable, at the holder's election, for shares of our common stock in either a cash or cashless exercise. The warrants have an exercise price equal to the greater of (i) $0.01 or (ii) eighty percent (80%) of the volume weighted average sale price per share of our common stock during the ten (10) consecutive trading days immediately preceding the notice of exercise. The number of warrants and exercise price are subject to adjustment in the event of the issuance of common stock as a dividend or distribution, and the subdivision or combination of the outstanding common stock. (See Note G[1](c).)

Note_G_Stockholders_Equity_Det4

Note G - Stockholders' Equity (Details) - Outstanding Warrants Activities (USD $)	3 Months Ended
	Mar. 31, 2014		Mar. 31, 2013	Dec. 31, 2013
Note G - Stockholders' Equity (Details) - Outstanding Warrants Activities [Line Items]	'		'	'
Shares Outstanding	8,470,836	[1]	'	8,470,336	[1]
Weighted Average Exercise Price	$0.69		'	$0.69
Exercisable at March 31, 2014	5,346,832		'	'
Exercisable at March 31, 2014	$0.81		'	'
Exercisable at March 31, 2014	'6 years 6 months		'	'
Granted	500		0	'
Granted	$0.34		'	'
Exercised	0		'	'
Exercised	$0		'	'
Canceled or expired	0		'	'
Canceled or expired	$0		'	'
Warrant [Member]	'		'	'
Note G - Stockholders' Equity (Details) - Outstanding Warrants Activities [Line Items]	'		'	'
Shares Outstanding	3,393,418		'	3,393,418
Weighted Average Exercise Price	$2.06	[2]	'	$2.06	[2]
Weighted Average Remaining Contractual Term	'6 years 109 days	[3]	'	'
Aggregate Intrinsic Value	$162,000		'	'
Exercisable at March 31, 2014	2,768,418		'	'
Exercisable at March 31, 2014	$2.63		'	'
Exercisable at March 31, 2014	'6 years 109 days	[4]	'	'
Exercisable at March 31, 2014	$162,000		'	'
Granted	0		'	'
Granted	$0		'	'
Exercised	0		'	'
Exercised	$0		'	'
Canceled or expired	0		'	'
Canceled or expired	$0		'	'
[1]	Figures include the impact of 405,000 options that were granted in 2011 to replace options / warrants previously granted to certain engineering personnel. The previously issued options / warrants will expire as the newer options vest on a one-to-one basis. During the fourth quarter of 2012, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011. Again during 2013, 134,998 of these options vested, and 98,332 previously issued options and 36,666 previously issued warrants were cancelled concurrently in conjunction with the vesting of the 2011 options. As of March 31, 2014, there are 135,004 of the 2011 options remaining to vest.
[2]	The weighted average exercise price for warrants outstanding as of January 1, 2014 and March 31, 2014 excludes 1,750,000 warrants with no determined exercise price.
[3]	The weighted average remaining contractual term for warrants outstanding as of March 31, 2014 excludes 763,500 warrants with no expiration date.
[4]	The weighted average remaining contractual term for warrants exercisable as of March 31, 2014 excludes 138,500 warrants with no expiration date.

Note_H_Commitments_and_Other_M1

Note H - Commitments and Other Matters (Details) (USD $)

1 Months Ended

3 Months Ended

38 Months Ended

0 Months Ended

3 Months Ended

3 Months Ended

1 Months Ended

Apr. 29, 2008

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Jan. 28, 2011

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2013

Oct. 04, 2010

Dec. 04, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2011

Dec. 13, 2010

Mar. 31, 2014

Mar. 31, 2013

Dec. 04, 2013

Jan. 31, 2013

Dec. 31, 2012

Mar. 31, 2011

Jul. 31, 2010

Oct. 04, 2010

West Virginia Remanufacturer [Member]

West Virginia Remanufacturer [Member]

BAIC [Member]

BAIC [Member]

BAIC [Member]

EBITDA Benchmark [Member]

Additional Hours [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

SCIRE Corporation [Member]

Business Plan Consultant [Member]

Business Plan Consultant [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

SCIRE Corporation [Member]

Note H - Commitments and Other Matters (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Monthly Rent Payment Under Operating Lease

$5,687

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual Rent Payment Under Operating Lease

68,244

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Rent Expense

'

17,000

17,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments Due, Next Twelve Months

'

68,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating Leases, Future Minimum Payments, Due in Two Years

'

28,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Officers' Compensation, Agreement, Base Rate (in Dollars per Year)

'

'

'

'

'

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

50,000

Income (Loss) from Continuing Operations before Interest Expense, Interest Income, Income Taxes, Extraordinary Items, Noncontrolling Interests, Net

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Professional Fees, Current

'

12,000

'

8,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,500

'

Sales Commission Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

4.00%

'

Professional Fees

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

17,250

'

'

Related Pary Transaction, Expenses from Transactions with Related Party, Rate (in Dollars per Hour)

'

'

'

'

'

'

'

'

'

'

125

'

'

'

200

'

'

2,000

3,840

3,840

'

'

'

Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

Deferred Compensation Arrangement with Individual, Revenue Benchmark

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

'

'

'

'

'

'

'

'

Due to Related Parties

'

'

'

'

'

'

'

'

'

'

'

3,000

'

'

'

'

'

'

'

'

'

'

'

Related Pary Transaction, Expenses from Transactions with Related Party, Rate (in Dollars per Month)

'

'

'

'

'

'

'

'

'

'

125

'

'

'

200

'

'

2,000

3,840

3,840

'

'

'

Related Party Transaction, Expenses from Transactions with Related Party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

12,000

'

'

'

'

'

'

Deferred Revenue

'

'

'

'

'

120,000

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recognition of Deferred Revenue

'

'

'

'

90,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Customer Advances and Deposits

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Value of Development Project

'

'

'

'

'

'

'

39,000

39,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid Expense and Other Assets, Current

'

$47,000

'

$31,000

'

'

$29,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'